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During my doctoral thesis I worked on three projects, investigating the function of 
erythropoietin (EPO) and its receptor (EPOR) in the brain. The projects aimed at a better 
understanding of the cellular and molecular basis of the previously described EPO-induced 
cognitive improvement found in mouse and man. These three projects were as following: 
 
1.) In vitro analysis of proliferation and differentiation     
 in EPO-treated neurospheres and primary hippocampal cultures  
 
 Result:  Erythropoietin reduces proliferation in neurospheres and  
   accelerates differentiation of neural precursors in neurosphere  
   and hippocampal cultures 
  
2.) Creation and analysis of a transgenic mouse line expressing a constitutively active 
 EPOR in GABAergic and glycinergic interneurons 
 
 Result:  Constitutively active EPOR in GABAergic and glycinergic   
   interneurons increases LTP but decreases acquisition learning   
 
3.) In vitro analysis of microglia motility after stimulation and examination of 
 underlying signaling pathways 
 
 Result:  Erythropoietin reduces microglia motility     
   and changes the phosphorylation kinetics of the ERK pathway 
 
Project 1 shows for the first time that EPO is able to increase the number of neurons and 
oligodendrocytes in the hippocampus of juvenile mice. This publication is currently in the 
process of revision. The manuscript with a description of my contribution is presented in the 
appendix. 
Project 2 includes the creation of a transgenic mouse line and its early analysis. The study 
is not ready to be submitted for publication yet. A plan of still to be performed experiments 
can be found in the outlook section.  
Project 3 is still work in progress and therefore not included in this thesis. First results 
showed reduced migration of stimulated EPO-treated primary microglia cultures. 
Additionally, changes in the phosphorylation kinetics of the ERK pathway could be observed 




































Erythropoietin (EPO) and its receptor (EPOR) are known to be essential for erythropoiesis. 
However, the EPO/EPOR system turned out to have additional important functions in non-
hematopoietic tissue. The brain is one of the target areas and both, EPO and EPOR, are 
expressed in the brain. EPO has been shown to be neuroprotective and to improve the 
cognitive performance of patients suffering from schizophrenia and multiple sclerosis. 
Interestingly, the mechanism of cognitive enhancement is also present in healthy individuals 
and genetic common variants of EPO/EPOR can actually influence cognitive performance. 
The cellular and molecular basis of this phenomenon is not totally understood and by 
systemically administered EPO, it is difficult to separate the direct effect on neural cells from 
hematopoietic effects through enhanced tissue oxygenation. In this study, a transgenic 
mouse line was generated expressing a constitutively active EPOR (cEPOR) in GABAergic and 
glycinergic interneurons in order to enable us to specifically examine the impact of 
EPO/EPOR on cognition, when expressed in inhibitory neurons. For this purpose, the cEPOR 
construct was inserted into the Viaat bacterial artificial chromosome (BAC) RP23-392P11 and 
microinjected into fertilized eggs of C57BL/6N females. Nine independent mouse strains 
were generated by breeding the founders with wildtype mice. The strains showed varying 
levels of construct expression and one strain actually had an insertion of different copy 
numbers in two different chromosomes. This relatively rare event in strain D14-0023 was 
further analyzed. Indeed, the offspring of D14-0023 segregated into low and high expressers, 
which was confirmed on the mRNA and protein levels. The phenotype of low and high 
expressers was then investigated in behavior and electrophysiological tests. Here, the basic 
behavior of the transgenic mice appeared to be comparable to wildtypes with respect to 
anxiety, olfaction, hearing, motor performance and pain perception. In the hole board 
working memory task, the transgenic mice showed a worse performance in rule learning in 
the acquisition phase, but no significant differences between the low and high expressers. 
Electrophysiological tests were conducted with the high expressers, measuring gamma 
oscillation and long term potentiation in the hippocampus. Whereas a significant influence 
of cEPOR could not be found in the gamma oscillation, short and long-term potentiation was 
increased. Hence, the study provides new information about the influence of the EPO/EPOR 
system on synaptic plasticity and cognitive performance. Importantly, the effects are pure 





1 Introduction  
1.1 Erythropoietin (EPO) 
Erythropoietin (EPO) is a hematopoietic growth factor and the main regulator of 
erythropoiesis. EPO is known to support the survival of erythroid progenitor cells by 
preventing their apoptosis and by inducing terminal differentiation (Jelkmann, 1992; 
Jelkmann and Metzen, 1996). Under normoxic conditions, the hormone's plasma levels are 
very low (10-11 M) which hindered the isolation and purification for a long time. Already in 
1906, Carnot described a humoral factor, which stimulated the red blood cell production 
(Fisher, 2010). In 1948, Bonsdorff and Jalavisto gave the humoral factor the present name 
'Erythropoietin'. It then took almost another 30 years before Miyake was able to purify EPO 
from the urine of aplastic anemia patients (Miyake et al., 1977). This was a milestone in the 
EPO research and important for its characterization, cloning (Jacobs et al., 1985; Lin et al., 
1985) and in vitro expression (Davis et al., 1987; Sasaki et al., 1987). After the promising 
results of Eschbach, showing that recombinant EPO (rhEPO) increases the hematocrit in 
anemic patients with end stage renal disease (Eschbach et al., 1987), rhEPO was approved in 
June 1989 by the American Food and Drug Administration for the treatment of patients with 
chronic renal failure (Fisher, 2003). At that time, rhEPO was first produced and put on the 
market by Amgen.  
Human EPO is a glycoprotein with a size of 30 kDa, although it appears with sizes of 30-
38 kDA in SDS-polyacrylamide gels (Jelkmann, 2004; Noguchi et al., 2008) because of 
different carbohydrate contents. EPO is composed of about 60 % protein and 40 % 
carbohydrate; the protein core is important for binding to its receptor and the 
carbohydrates stabilize the hormone by preventing degradation. The human EPO gene is 
located on chromosome 7 (q11-22), it includes five exons and four introns, and codes for a 
single polypeptide with 165 amino acids. The sequence is highly conserved and the murine 
gene, located on chromosome 5, shows 80 % homology to the human protein.  
The EPO expression in fetal liver and adult kidney can be upregulated under hypoxic 
conditions up to 1000-fold (Ebert and Bunn, 1999). The transcription of the EPO gene is 
enhanced by binding of the hypoxia inducible factor (HIF) to the hypoxia-responsive element 




1992). Under normoxic conditions HIF1-α is hydroxylated by prolyl hydroxylases, which 
enables the binding of the von Hippel-Lindau factor, leading to ubiquitination and 
degradation in the proteasome. Under hypoxic conditions HIF1-α forms a dimer with HIF1-β, 
which bind to the HRE. However, the regulation of the EPO gene is cell-type specific. The 
utilization of the promoter varies between different cell types and another HRE was also 
found in the EPO 5' UTR (Haase, 2010). Additionally, it has to be noted that HIF2-α may be 
more important for EPO gene regulation than HIF1-α, which might preferentially enhance 
VEGF and GLUT-1 transcription (Noguchi et al., 2008). 
 
1.2 EPO receptor (EPOR) 
With the availability of pure rhEPO, the search for its receptor and signaling pathways 
started, leading to the first publication in 1987, where the murine EPOR (mEPOR) was 
identified in primary erythroid progenitor cells by cross-linking studies with radiolabled 125I-
EPO (Sawyer et al., 1987). Only two years later, the mEPOR was cloned and isolated from a 
pMX expression library made from a murine erythroleukemia cell line (D'Andrea et al., 
1989). In 1990, the human EPOR (hEPOR) was isolated from the human erythroleukemia cell 
line OCIM1 and fetal liver (Jones et al., 1990) and found to share around 82 % homology with 
the mEPOR. The mEPOR gene spans around 5 kb, contains eight exons, and produces a 507 
amino acid protein with a predicted molecular weight of 55 kDa (Youssoufian et al., 1990). 
Glycosylation of the EPOR causes the protein to appear with a size of 66 kDa in SDS-
polyacrylamide gels. Additional phosphorylation can shift the protein size even up to 72 kDa 
(Youssoufian et al., 1993). The EPOR contains a single hydrophobic transmembrane domain, 
separating the extracellular from the intracellular domain. The extracellular domain contains 
4 conserved cysteine residues and a Trp-Ser-X-Trp-Ser (WSXWS) motif, which classifies the 
EPOR as a cytokine class I receptor (Constantinescu et al., 1999a). The intracellular domain is 
divided into two functional regions. One is the membrane-proximal region, which contains 
two conserved domains, box1 and box2. Since the EPOR has no intrinsic kinase activity, this 
domain is of special importance, because it is the binding site for the Janus kinase 2 (JAK2). A 
deletion of 20 amino acids in this conserved area eliminates any mitogenic effect as well as 
the phosphorylation of the receptor (Miura et al., 1991). The second domain is the 





several signaling molecules (Tilbrook and Klinken, 1999). In deletion models, it was found 
that the distal region can function as a negative regulator (D'Andrea et al., 1991) and is 
important for signal termination. 
For a long time, it was thought that EPO binding induces homodimerization of the EPOR. But 
in 1999, crystallography gave evidence for a preformed EPOR homodimer (Livnah et al., 
1999). Binding of EPO leads to conformational changes allowing the trans-phosphorylation 
by JAK2, which was discovered to be the protein tyrosine kinase transmitting the EPO 
activation signal (Witthuhn et al., 1993). The signaling pathways known to be activated by 
EPO include the signal transducers and activators of transcription (STATs), the mitogen-
activated protein kinase (MAPK), the phosphoinositol-3-kinase (PI3K/AKT) and nuclear factor 
(NF)-кB. The protein tyrosine phosphatase SHP-1 was found to bind at Y429 and to play a 
major role in signal termination (Klingmüller, 1997; Klingmüller et al., 1995).  
Similar to the expression of EPO, the expression of EPOR is cell-type specific. The promoter 
contains no TATA or CCAAT sequence, which is typical for genes that are regulated in a tissue 
specific manner. Early promoter-fusion studies showed that the −581 to −130 promoter 
element stimulates the expression of EPOR in erythroid cells but not in fibroblasts 
(Youssoufian et al., 1990). Later, it was proven that the hematopoietic transcription factor 
GATA-1 binds to this region of the promoter (Zon et al., 1991) and enhances the 
transcription of EPOR in hematopoietic cells. GATA-1 expression is known to be restricted to 
hematopoietic tissue. Therefore, EPOR under the GATA-1 promoter was used to rescue 
complete EPOR knockout mice and to analyze the effect of EPO/EPOR in non-hematopoietic 
tissues (see 1.5.3). 
 
1.3 EPO/EPOR system in the brain 
1.3.1 EPO/EPOR expression 
EPO and the EPOR were first found to be important for erythropoiesis and it took some time 
until the first results indicated an additional role of the system in non-hematopoietic tissues, 
like the brain. In order for the EPO/EPOR system to play a role in other tissues, these cells 
would have to express EPO and/or the EPOR. This was difficult to prove for the EPOR. So far, 
there is no reliable antibody for the EPOR available on the market (Elliott et al., 2006; 




least two independent methods to find EPOR expressing cells, both have their pitfalls. The 
first method is to measure the mRNA expression (which does not prove that the EPOR is 
translated into protein and that the receptor is located in the membrane) and the second 
method is to indirectly measure the existence of the receptor by ligand binding or signaling 
pathways (with this method, it cannot be excluded that EPO binds to another protein or 
receptor). There are many publications showing positive results of EPO and/or EPOR 
expression and effects in non-hematopoietic tissues (explained in detail on the following 
pages), but there is also a small fraction of researchers doubting functional EPOR expression 
and effects of the EPO/EPOR system in non-hematopoietic cells (Sinclair et al., 2010). 
 
EPO expression in non-hematopoietic cells 
One of the first indications for EPO expression in non-hematopoietic tissue was published in 
1992. EPO mRNA was found to be increased after hypoxia, not only in the liver and kidney, 
but interestingly also in testis and brain of adult rats (Tan et al., 1992). Figure 1, a picture 
from that study, is of particular interest for two reasons. First, it shows that EPO is not only 
expressed in developmental stages, but also at low levels in the adult brain. Secondly, the 
expression can be increased with hypoxia, which is important with regard to ischemia and 
neuroprotection.  
 
Figure 1: Detection of EPO mRNA with autoradiography (from Tan et al., 1992). ST = Supratentorial portion of 
the brain, IT = Infratentorial portion of the brain. 
 
In 1994, in another study published by Masuda (Masuda et al., 1994), EPO protein was 
detected in cerebral rat cultures using enzyme linked immunoassays. Like in the previous 
study, EPO expression was stimulated under hypoxia. Analyses to detect the cell type 
producing EPO showed that astrocytes are the main source of EPO production, whereas no 
EPO production could be detected in microglia. Interestingly, the growth and differentiation 





the authors postulated a paracrine mechanism for EPO in the brain (in contrast to the 
endocrine mechanism in the hematopoietic system). Astrocytes produce EPO for direct 
communication with closely located neurons or other glial cells. Therefore, the lower binding 
affinity of the EPOR found in PC12 cells (Masuda et al., 1993) could be overcome through 
higher EPO concentrations. In 1999, EPO mRNA expression was found in cerebral mouse 
neuron cultures (Bernaudin et al., 1999) and in 2002, EPO mRNA was also found to be 
expressed at very high levels in rat oligodendrocyte cultures (Sugawa et al., 2002). So far, it is 
not clear if microglia are able to express EPO. Until today, EPO expression in the human 
brain was reported for astrocyte cultures, but was not detectable in neuron, 
oligodendrocyte or microglia cultures (Nagai et al., 2001).  
 
EPOR expression in non-hematopoietic cells 
In 1994, Liu et al. showed endogenous expression of the EPOR on mRNA level in embryonic 
mice (Liu et al., 1994). The expression at E10 was found to be relatively high. Remarkably, it 
was found to be higher than in adult bone marrow or spleen, and decreased with 
development to non-detectable values at day E16. Later, the 
same author published a second article with a transgenic 
mouse carrying a fusion product of the hEPOR promoter 
(-1778 to +1) and a β-galactosidase reporter (Liu et al., 1997). 
At E9.5, the expression can be nicely visualized in the neural 
tube (Figure 2). As in the first study, the authors could not 
detect any expression of EPOR in the adult brain. However, 
the study did not include the application of hypoxia. 
 
Figure 2: hEpoR/β-galactosidase reporter gene expression at E9.5. The 
blue color shows the expression in the neural tube of the mouse embryo 
(from Liu et al., 1994). 
 
 
A different study published in 1995, demonstrated an increase of EPO and EPOR mRNA in 
the adult mouse brain under hypoxic conditions (Digicaylioglu et al., 1995). Interestingly, 
radiolabeled 125I-EPO was shown to bind mainly in the capsula interna, the corpus callosum 
and the fimbria of the hippocampus, indicating the location of the EPOR expression in the 
adult brain for the first time. Later, our group was able to show hypoxia-induced mRNA 




additionally showed protective effects of EPO by reduced cell death. It is therefore likely that 
one role of EPO/EPOR in the adult brain is associated with ischemia and may be important 
for neuroprotection. Finally, a number of studies showed that the EPOR is not only 
expressed in neurons, but also in astrocytes, oligodendrocytes and even microglia (Marti et 
al., 1996; Nagai et al., 2001; Sugawa et al., 2002).  
 
1.3.2 Role for EPO/EPOR in neuroprotection  
There are many publications demonstrating the neuroprotective function of EPO and various 
reviews summarizing the most important findings (Brines and Cerami, 2005; Sargin et al., 
2010). EPO was shown to be neurotrophic, angiogenic, anti-oxidative, anti-inflammatory, 
anti-apoptotic, and stem cell modulating. This line of research started in 1993 when EPO was 
shown for the first time to increase the survival of ChAT neurons after unilateral fimbria-
fornix dissection (Konishi et al., 1993). A few years later, a protective effect of EPO on 
neurons from glutamate neurotoxicity could be demonstrated (Bernaudin et al., 1999; 
Morishita et al., 1997; Sakanaka et al., 1998). One caveat, that needs to be considered with 
these in vitro studies, is that the EPO treatment has to be applied at least 8 h before the 
incubation with glutamate to be protective. Therefore, these in vitro data are not very 
helpful regarding the clinical implementation of EPO as a neurotherapeutic drug in acute 
stroke. However, the results of in vivo experiments done by Sakanaka et al. in 1998 are very 
impressive (Sakanaka et al., 1998). The authors implanted small minipumps for 
intracerebroventricular infusion of EPO or soluble EPOR (sEPOR) directly into the brain of 
gerbils. They then applied ischemia by middle cerebral artery occlusion (MCAO) for 3 min 
and showed improved learning abilities after EPO treatment. They also applied mild ischemia 
(2.5 min) which did not lead to significant cell death under normal conditions (Figure 3D). 
Interestingly, there was a significant reduction in the total number of pyramidal neurons in 
CA1 and increased cell death after infusion with sEPOR, which is able to neutralize 
endogenous EPO (Figure 3C). Taken together, these experiments provide conclusive 
evidence for the protective effect of endogenous EPO in the brain. As discussed by Brines 
and colleagues (Brines et al., 2000) intrathecal administration of EPO is not practical in most 
clinical contexts. Thus, the authors applied MCAO in male rats and injected EPO 
intraperitoneal before, simultaneously, or after the occlusion. EPO was able to reduce the 





question for applying EPO systemically is, whether and how EPO is transported over the 
blood-brain barrier (BBB) into the brain. Using biotinylated EPO they could demonstrate that 
EPO is able to cross the BBB within 5 h in healthy mice. This time frame is comparable to 
humans, where intravenously injected indium labeled EPO can be found in the cerebral 
spinal fluid after 5-7 h (Ehrenreich et al., 2004). However, the mechanism is still not clear, 
but is thought to be a receptor-mediated transport. 
 
Figure 3: Effects of the intracerebroventricular infusion of sEPOR in the pyramidal layer of CA1 in gerbils. (A) 
Cresyl violet staining of the hippocampal CA1 field after sEPOR infusion. (B) Cresyl violet staining of the 
hippocampal CA1 field after vehicle infusion. (C) TUNEL staining of the hippocampal CA1 field after sEPOR 
infusion. (D) TUNEL staining of the hippocampal CA1 field after vehicle infusion. (from Sakanaka et al., 1998). 
1.3.3 EPO/EPOR signaling in the brain 
In 2001 our group provided evidence that EPO/EPOR signaling in the brain is comparable to 
EPO/EPOR signaling in the hematopoietic system (Sirén et al., 2001). Hippocampal neuron 
cultures showed an activation of STAT5, MAPK, and PI3K/AKT after EPO treatment under 
hypoxic conditions. Afterwards, another article, published in Nature, identified the activation 
of NF-кB in neurons after EPO treatment (Digicaylioglu and Lipton, 2001). Thus, all major 
signaling pathways activated in erythrocytes can be found in neurons (Figure 4).  
 




1.4 EPO/EPOR and cognition 
1.4.1 Evidence in humans 
With its promising neuromodulatory function, it seemed likely that rhEPO could be used as a 
neurotherapeutic drug for stroke and neurotrauma as well as neuroinflammatory and 
neurodegenerative diseases. The first human trials showed mainly positive outcomes. The 
first clinical study on stroke patients demonstrated improvement in outcome scales and 
reduced infarct sizes in rhEPO treated patients (Ehrenreich et al., 2002; Ehrenreich et al., 
2011). This result was confirmed in the second trial, phase II/III for patients not receiving 
rtPA, but not for patients simultaneously receiving thrombolytic drugs (Ehrenreich et al., 
2011; Ehrenreich et al., 2009). Nonetheless, the stroke study from 2002 is not the only 
clinical study in humans showing beneficial effects of rhEPO treatment. Multiple sclerosis 
(MS) as well as schizophrenia are medical conditions sharing neurodegenerative features 
and thus, human treatment trials for these disorders with rhEPO were initiated. 
Interestingly, rhEPO was able to improve the cognitive performance in chronic MS and 
schizophrenic patients (Bartels et al., 2008; Ehrenreich et al., 2007a; Ehrenreich et al., 
2007b). In 2011, a study suggested a possible mechanism of EPO action in schizophrenic 
patients, showing that EPO counteracts the gray matter loss (Wüstenberg et al., 2011). 
Recently, a study was published showing that the genetic composition of common variants 
in the EPO and EPOR gene are associated with the cognitive performance of schizophrenic 
patients and healthy controls (Kästner et al., 2012). Studies from other groups expand the 
application range of rhEPO to mood disorders, by showing anti-depressant-like effects in 
humans and mice (Miskowiak et al., 2012). 
To summarize, the EPO/EPOR system influences cognition, not only in disease conditions, 
but interestingly also in healthy subjects (Kästner et al., 2012; Miskowiak et al., 2007). The 
molecular mechanism behind is still not fully understood, but animal studies may offer 
further insight in the future.  
1.4.2 Evidence in mice 
Several animal studies were designed to examine the effects of rhEPO on cognition. In 2008, 
Adamcio et al. showed that a three week long rhEPO treatment in juvenile healthy mice 
increases the long term potentiation (LTP) and hippocampal memory (Adamcio et al., 2008). 





executive function and attention in healthy juvenile mice treated with EPO (El-Kordi et al., 
2009). The 5CSRTT is challenging for mice and the study showed that EPO-treated animals 
have a higher probability to finish the task. In both studies, EPO was administered by i.p. 
injection. The question whether or not the positive effects are at least partially transmitted 
via the hematopoietic system and enhanced tissue oxygenation cannot be answered by such 
studies. Therefore, a transgenic mouse line with a constitutively active EPOR in pyramidal 
neurons was developed and analyzed in our group (Sargin et al., 2011). These mice show 
increased LTP as well as enhanced cognitive functions, but also increased impulsivity (see 
also 1.6.3). 
 
1.5 EPO and EPOR knockout mice 
1.5.1 EPO-/- and EPOR-/- - Effects on the hematopoietic system 
The first EPO and EPOR mouse models were complete knockouts (EPO-/- or EPOR-/-) and 
primarily used to understand the role of EPO in the hematopoietic system. At almost the 
same time, three different groups generated and published EPO-/- or EPOR-/- knockout mice 
with comparable results (Kieran et al., 1996; Lin et al., 1996; Wu et al., 1995). All knockout 
animals were generated by disrupting the EPO or EPOR gene by homologous recombination. 
The heterozygous animals appeared normal, were viable and fertile, and showed no changes 
in hematocrit (Wu et al., 1995). The homozygous knockouts of EPO or EPOR exhibited 
identical phenotypes which are characterized by reduced primitive erythropoiesis and early 
death around E13 because of failure of definitive fetal liver erythropoiesis (severe anemia). 
Similar results were published for the EPOR knockout by Lin and Kieran (Kieran et al., 1996; 
Lin et al., 1996). All three labs analyzed the erythropoiesis of EPOR-/- mice in vivo and in vitro. 
In vivo, the peripheral blood of the wildtype (wt) mice included yolk sac-derived erythroid 
cells (mature erythrocytes with nucleus), normoblast (n), and mature enucleated 
erythrocytes (m) (Kieran et al. 1996; Figure 5B). The liver blood contained proerythroblast 
(p), normoblasts (n) and mature enucleated erythrocytes (m) (Kieran et al. 1996; Figure 5C). 
But neither the peripheral blood nor the liver blood of the EPOR-/- mice revealed 
hemoglobinized normoblast (n) or mature enucleated erythrocytes (m). This demonstrates 
the importance of the EPO/EPOR system for the differentiation of proerytroblasts to further 





Figure 5: Phenotypical comparison of wildtype (wt) and EPOR
-/-
 knockout E12.5. (A) Wt embryo E12.5. (B) 
Peripheral blood cells of wt E12.5 (May-Grunwald-Geimsa staining). (C) Fetal liver blood cells of wt E12.5 (May-
Grunwald-Geimsa staining). (D) EPOR
-/-
 embryo E12.5. (E) Peripheral blood of EPOR
-/-
 E12.5 (May-Grunwald-
Geimsa staining). (F) Fetal liver blood of EPOR
-/-
 E12.5. (May-Grunwald-Geimsa staining). Abbreviations: y= 
primitive yolk sac-derived erythroid cells, n=normoblasts, m=mature enucleated red cells, p=proerythroblasts. 
(A and D from Lin et al., 1996; B, C, E and F from Kieran et al., 1996). 
 
1.5.2 EPO-/- and EPOR-/- - Effects on non-hematopoietic tissues 
Based on the first indications that the EPO/EPOR system might play a role in many tissues, 
EPO-/- and EPOR-/- knockouts were analyzed again with regard to non-hematopoietic tissues. 
The first publication in 1999 showed impaired cardiac development and disrupted 
vascularization in EPOR-/- (Wu et al., 1999). The cardiac hypoplasia, evident from E12.5 on, 
was likely due to a reduction in proliferation of cardiomyocytes and not due to an increase in 
apoptosis. Interestingly, the mRNA of EPOR in wildtype mice was not found in the 
myocardium itself, but transient expression was detected in endo-, epi- and pericardium 
from E10.5 to E13.5. Therefore, the authors suggested a non-cell-autonomous mechanism of 
EPO on cardiomyocyte proliferation. In this study, no effect was found for brain tissue. 
However, in 2002, the first data showing effects in the developing brain of EPOR-/- mice were 
published (Yu et al., 2002). As early as of E10.5, the authors found increased apoptosis in the 
cerebral cortex and neuroepithelium of the midbrain. In cortical cultures of E10.5 knockout 
mice, they detected less nestin positive progenitor cells and after four days less microtubule- 
associated protein 2 (MAP2) positive mature neurons. Under normoxic conditions, no 





in cell cultures of knockout animals under hypoxic conditions. The results from the complete 
knockout suggest that EPO/EPOR signaling is important for proliferation and survival of non-
hematopoietic progenitor cells. However, it cannot be ruled out that the effects are caused 
indirectly by the general state of hypoxia, due to the reduction of mature erythrocytes.  
1.5.3 EPOR-/- knockouts rescued for the hematopoietic lineage 
To circumvent the issue that the effects found in non-hematopoietic tissues might be caused 
indirectly by a general state of hypoxia, an EPOR-/- knockout mouse was rescued for the 
hematopoietic system (Suzuki et al., 2002). This was achieved by using the EPOR-/- knockout 
with transgenic expression of the EPOR under the control of the GATA-1 hematopoietic 
regulatory domain (GATA1-HRD-EPOR). The EPOR-/- TgEPORE mice initially developed 
normally and were fertile, but later developed obesity and insulin resistance (Teng et al., 
2011). The mice were also less active, had decreased energy expenditure, and increased fat 
mass. Interestingly, wt mice express high levels of EPOR in the hypothalamus, most likely in 
proopiomelanocortin (POMC) neurons and EPOR-/- TgEPORE animals showed decreased 
mRNA levels of POMC. These results suggest a non-hematopoietic effect of EPO on energy 
homeostasis. 
1.5.4 EPOR-/- conditional knockout 
Conditional knockouts were generated by crossbreeding of EPORfloxp/floxp mice with hGFAP-
Cre+ mice (Tsai et al., 2006). The hGFAP promoter activity and specific expression in the 
central nervous system starting at E13.5 had been reported by an earlier study (Zhuo et al., 
2001). The hGFAP+ radial glial cells generate almost all cortical projection neurons during 
development (Malatesta et al., 2003) and are also known to constitute the stem cells in the 
adult brain. The conditional knockouts were viable and fertile, showing that the expression 
of EPOR after E13.5 is not essential for survival. However, the animals showed less 
proliferating cells in the subventricular zone, which was also reduced in total size. 
Furthermore, the animals showed an impaired post-stroke recovery with decreased 





1.6 Activating mutations in the EPOR Gene 
1.6.1 Natural occurring mutations in the human EPOR Gene 
Primary familial and congenital polycythemia, also known as familiar erythrocytosis, is 
caused by autosomal dominant mutations of the EPOR gene, causing elevated levels of red 
blood cells. So far, there are 16 mutations known in humans and 14 of them result in a 
truncated version of the EPOR (Huang et al., 2010). The first mutation, leading to a 70 C-
terminal truncation (G6002A), was found 1993 in a Scandinavian family (de la Chapelle et al., 
1993). This stirred a sensation, because one of the positive test subjects was Eero Antero 
Mäntyranta, the successful cross-country skier and multiple Olympic champion (Longmore, 
1993). In 1991, it had already been shown that familiar erythrocytosis is coupled with 
hypersensitivity of erythroid progenitor cells to EPO (Juvonen et al., 1991) and that this form 
of erythrocytosis has no obvious effects on health or life-span. At the same time, it was 
reported that the cytoplasmic C-terminus of the murine EPOR contains negative growth-
regulatory domains (D'Andrea et al., 1991). C-terminal truncation of the receptor allowed 
Ba/F3 cells to grow with 1/10 of the normal required EPO concentration, which nicely 
mimics the human data. In 2001, a mouse model for congenital polycythemia was developed 
by replacement of the murine EPOR with the mutated human EPOR (Divoky et al., 2001). The 
mice were a phenocopy of the human disorder and showed increased hematocrit and higher 
sensitivity of erythroid progenitor cells to EPO. 
1.6.2 Murine constitutively active EPOR (cEPOR)  
The analysis of the truncated versions of the EPOR was initiated by Akihito Yoshimura, who 
developed a mutating cell-culture system for EPOR with Ba/F3 cells (Yoshimura et al., 1990). 
Ba/F3 cells are naturally interleukin-3 (IL-3) dependent, but the expression of the EPOR 
allows the cells to grow in the presence of EPO without IL-3. Yoshimura infected the cells 
with a retrovirus expressing the murine wildtype EPOR, hoping that with replication and 
packaging spontaneous mutations would occur. By decreasing the concentrations of EPO, 
the authors selected two mutants, one with a C-terminal truncation and hypersensitivity for 
EPO and a second one with a point mutation leading to growth factor independent 
proliferation and survival. The point mutation, a transition from C to T at nucleotide 484, 
causes a substitution in the exoplasmic domain from arginine (R) to cysteine (C) at codon 





vector pMX for further analysis. In following experiments it 
was shown that not the loss of the arginine but the presence 
of the new cysteine is required for the constitutive activity 
(Watowich et al., 1992). Furthermore, it was observed that 
cEPOR was able to form disulfide-linked homodimers (Figure 
6). It is thought that the covalent dimerization leads to 
conformational changes comparable to EPO binding, thereby 
inducing the constitutive activity of the receptor. 
 
Figure 6: Illustration of the disulfide-linked homodimers of cEPOR 
(from Constantinescu et al., 1999b). 
 
 
1.6.3 Transgenic mouse models with cEPOR 
In a previous study of our group, cEPOR was expressed under the alpha-CaMKII promoter in 
pyramidal neurons (Sargin et al., 2011). The mice were viable and fertile, and showed no 
obvious neuropathology, no change in body weight, mating behavior, or hematocrit. 
However, compared to wildtype mice, they showed increased hippocampal-dependent 
learning, social memory and attention, but were also significantly more impulsive. In 
addition, an increase in LTP was reported. Therefore, the model proves that the EPO-EPOR 
system is able to enhance neuronal plasticity and cognition independently of the blood 
system. Furthermore, the study compares the phenotype of transgenic mice with the effects 
of systemically administered EPO (Table 1). 
 
Table 1: Comparison of the effects of systemically administered EPO with the alpha-CaMKII-HA-cEPOR-mice. 
= no change,  increase (from Sargin et al., 2011).  
 
Interestingly, the transgenic animals show hyperactivity and impulsivity, which in contrast 
cannot be found after systemic EPO administration. This might be explained by an imbalance 




signaling in excitatory and inhibitory neurons, whereas the transgenic mice are stimulated 
only in excitatory pyramidal neurons. This might lead to an imbalance and a relative deficit 
of inhibition, thereby explaining hyperactivity and impulsivity. This led to the interest in the 
role of the EPO/EPOR system in inhibitory neurons and their impact on cognition.  
1.7 Aim of the study 
In general, it is now widely accepted that EPO influences cognition, but there are many open 
questions as to how EPO is able to improve cognitive functions in mouse and man. There is 
still an ongoing debate as to whether or not the positive effects are caused via the 
hematopoietic system and enhanced tissue oxygenation. To date, it has been difficult to 
exclude the effect of the hematopoietic system, because the majority of the studies 
measuring cognitive performance are using rhEPO intravenously or intraperitoneally. Of 
course, cell culture models can exclude the effect of the hematopoietic system, but in this 
case it is difficult to make a connection to cognition. To analyze the role of the EPO/EPOR 
system in cognition, it is necessary to activate or inactivate the signaling in specific neuronal 
subpopulations. In the study mentioned above (Sargin et al., 2011), the constitutively active 
EPOR (cEPOR) was expressed in excitatory pyramidal neurons. The logical counterpart would 
be a transgenic mouse line with cEPOR in inhibitory interneurons.  
Thus, the aim of the current study was to generate a transgenic mouse line expressing 
cEPOR in inhibitory interneurons and to analyze the impact of this genetic manipulation on 
cognition. The cEPOR was placed under the control of the vesicular inhibitory amino acid 
transporter (Viaat) promoter, which should lead to expression of cEPOR in all gammaamino 
butyric acid (GABA)ergic and glycinergic neurons. 
This novel mouse model was used to investigate the function of the EPO/EPOR system in 
inhibitory neurons and to provide insight into the mechanism by which cEPOR expression 
modulates cognition. Importantly, all effects reported in this study are pure neural effects, 









The methods section is divided into the following parts:  
Part I  - Cloning of the Viaat-HA-cEPOR construct  
Part II  - Analysis of the transgenic Viaat-HA-cEPOR mouse  
Methods Part I 
2.1 DNA preparation 
Plasmid DNA preparation is a method to extract and purify plasmid DNA amplified in 
bacteria. Depending on the size of the bacterial culture, it is named mini, midi or maxi 
preparation.  
2.1.1 Mini preparation 
The mini preparation is mainly used to screen clones for correct DNA constructs. 12 clones 
were picked and grown overnight in 5 ml culture medium at 37 °C. For plasmid DNA, 1.5 ml 
were used for a crude plasmid isolation (boiling method) and a diagnostic restriction digest. 
The pellet of 3.5 ml was stored at -20 °C, until the results of the digest show clones with 
correct fragment sizes. The DNA from 2-4 positive clones was isolated and purified using a 
column based plasmid mini kit for sequencing and further processing.  
 
Plasmid mini preparation (boiling method) 
The boiling method is a crude and fast method. The resulting plasmid DNA is contaminated 
with proteins and bacterial genomic DNA. This is why the method is also called "dirty mini 
preparation". However, for the diagnostic restriction digest the purity is not important and 
the method is much cheaper compared to the column-based plasmid mini kit.  
For the preparation of plasmid DNA, the pellet of the 1.5 ml overnight culture was 
resuspended in 300 µl STET buffer and shaken for 5 min. The lysozyme solution was freshly 
prepared (10 mg/ml - 0.01 g in 1 ml STET) and 25 µl were added. After heating for 1 min at 
100 °C, the preparation was cooled down on ice for 2 min and centrifuged for 10 min at 
15,000 rpm at room temperature (RT). The pellet was removed with a toothpick. For 





mixture vortexed. The centrifugation was started immediately for 30 min at 15,000 rpm at 
RT. The supernatant was discarded and the pellet dried. The dried pellet was dissolved in 
50 µl TE for 30 min at 37 °C on a shaker. For the diagnostic restriction digest 5 µl were used.  
 
Plasmid mini preparation (Column based - Life Technologies) 
To obtain plasmid DNA with high purity, the PureLink Quick Plasmid Miniprep Kit (Life 
Technologies) was used. This is an alkaline/SDS based DNA isolation kit containing a silica 
membrane column. The preparation was done according to the manufacturer's protocol 
with minor modifications. The pellet of the 3.5 ml overnight culture was resuspended in 
250 µl resuspension buffer (R3, containing RNaseA). After adding 250 µl of the lysis buffer 
(L7), the solution was mixed carefully by 5 times inversion of the tube. The solution was 
incubated for 5 min at RT, 350 µl of the precipitation buffer (N4) were added, and the tube 
was inverted immediately. The solution was centrifuged at 11,000 rpm for 10 min at RT. The 
supernatant was loaded onto the spin column and centrifuged for 1 min at 11,000 rpm at RT. 
The flow-through was discarded and 700 µl washing buffer (W9) were added. After 
centrifugation at 11,000 rpm at RT and discarding the flow-through, the column was dried by 
centrifugation for 1 min at 11,000 rpm at RT. The column was placed in a clean tube, 40 µl 
EB buffer (preheated to 65 °C) was added and incubated for 1 min, followed by elution by 
centrifugation at 11,000 rpm at RT. It is important to use EB buffer or water for the elution 
and not TE buffer if the samples are to be sequenced. TE buffer contains 
ethylenediaminetetraacetic acid (EDTA) which chelates Mg2+ ions, which are important for 
the activity of the Taq polymerase during sequencing. 
 
BAC mini preparation (Qiagen) 
For the isolation of BAC DNA, the Plasmid Mini Kit (Qiagen) was used with a slightly modified 
protocol (Liu et al., 2003). An overnight culture of 5 ml was centrifuged for 1 min at 
15,000 rpm at RT. The pellet was dissolved in 250 µl of P1 buffer. Then, 250 µl lysis buffer P2 
were added. The tube was very carefully inverted 4-6 times and incubated for 5 min at RT. 
350 µl of the precipitation buffer N3 were added and the tube was again inverted 4-6 times. 
Especially for BAC DNA, the inversion is a critical step and has to be done very gently, since 
the risk of shearing the large molecule is very high. After centrifugation at 12,000 rpm for 





for 4 min. Because the large BAC DNA would be difficult to elute from the silica membrane, 
the supernatant was not applied to a spin column. Instead, the DNA was precipitated by 
adding 750 µl isopropanol. The tubes were again inverted carefully 4-6 times and incubated 
for 10 min at RT. After centrifugation at 15,000 rpm for 10 min at RT, the pellet was washed 
with 70 % ethanol, dried, and dissolved in 50 µl EB buffer. 
2.1.2 Midi preparation 
The plasmid midi preparation was done with the PureLink HiPure Plasmid Midiprep Kit (Life 
Technologies). The midi preparation was done according to the manufacturer's protocol with 
minor modifications. 50 ml of an overnight culture were centrifuged for 15 min at 3,500 rpm 
and in parallel the column was equilibrated with 15 ml of equilibration buffer (EQ1). The 
pellet was dissolved in 10 ml resuspension buffer (R3) with RNase A. The cells were lysed 
with 10 ml L7 buffer and the Falcon tube was inverted 5 times before incubation for 5 min at 
RT. For precipitation, 10 ml of N3 buffer were added and the Falcon tube was inverted 5 
times. The suspension was loaded onto the column through a filtration cartridge and filtered 
by gravity flow. The cartridge and the flow-through were discarded and 20 ml washing buffer 
(W8) were added and drained by gravity flow. The plasmid DNA was eluted with 5 ml elution 
buffer (E4) again drained by gravity flow. In the following step, the eluted DNA was 
concentrated with an isopropanol precipitation. Therefore, 3.5 ml isopropanol were added 
and mixed by vortexing. After 2 min of incubation the solution was centrifuged for 45 min 
with 3,500 rpm at 4 °C. The supernatant was discarded and the pellet was washed with 70 % 
ethanol and dried for approximately 5 min. The dried pellet was dissolved in 50 µl EB buffer.  
2.1.3 Maxi preparation 
Plasmid maxi preparation (Column based - Life Technologies) 
For the plasmid maxi preparations, the PureLink HiPure Plasmid Maxiprep Kit (Life 
Technologies) was used. This kit enables the isolation and purification 500-850 µg plasmid 
DNA. The preparation was done according to the manufacturer's protocol with minor 
modifications. 200 ml of the overnight culture was distributed in 4x 50 ml Falcon tubes and 
centrifuged 15 min at 3,500 rpm. With starting the centrifugation step, the temperature was 
reduced to 4 °C. During centrifugation, the column was equilibrated with 30 ml EQ1. After 
centrifugation, the pellet was dissolved in 10 ml resuspension buffer (R3) and 10 ml lysis 





For precipitation, 10 ml of N3 buffer were added and the Falcon tubes were inverted 
immediately to avoid localized precipitation. The suspension was transferred into a cartridge 
containing an equilibrated column. After removing the cartridge, the column was washed 
with 50 ml washing buffer W8. The DNA was eluted with 15 ml elution buffer E4. To 
precipitate the DNA, 10.5 ml isopropanol were added and the Falcon tube was centrifuged 
for 45 min at 3500 rpm at 4 °C. The pellet was washed and transferred with 1 ml 70 % 
ethanol into a 1.5 ml Tube and centrifuged for 4 min at 11,000 rpm at RT. The supernatant 
was removed carefully. The dried pellet was dissolved in 50-100 µl EB buffer.  
 
BAC Maxi preparation (MACHERY-Nagel) 
For the BAC Maxi preparations, the column based Kit from MACHERY-NAGEL was used. This 
kit enables the isolation and purification 100 µg BAC DNA over an anion-exchange resin 
column. The preparation was done according to the manufacturer's protocol with minor 
modifications. An overnight culture of 250 ml was distributed to 5x 50 ml Falcon tubes and 
centrifuged for 30 min with 3,500 rpm at 4 °C. The pellets were resuspended in a total 
volume of 24 ml S1 buffer and distributed to 2x 50 ml Falcon tubes. The cells were lysed with 
12 ml S2 buffer and mixed carefully by inversion. After incubation for 5 min at RT, the 
precipitation buffer S3 was added. The Falcon tubes were inverted immediately and 
incubated for 10 min on ice. The suspension had to be cleared from the precipitated protein 
and cell debris before loading onto the column. This was done with a filter, wetted with 
ddH2O, placed in an appropriate funnel. The flow-through was collected in a Falcon tube. 
The column was equilibrated with 6 ml N2 buffer, before adding the cleared lysates from 
both Falcon tubes onto one column. The column was washed twice with 18 ml N3 buffer and 
the BAC DNA was eluted 3 times with 5 ml preheated (55 °C) N5 buffer. For precipitation 
11 ml of isopropanol were added. The Falcon tube was inverted carefully a few times to 
ensure proper mixing. The solution was distributed to 3 round bottom Greiner tubes for 
centrifugation at 12,000 rpm for 25 min at 4 °C. The supernatant was discarded and the 
pellets were dried. The BAC DNA was dissolved in 20 µl EB buffer by incubation at RT for 
30 min and the solution transferred very carefully into a 1.5 ml tube. If the solution was too 
viscous for pipetting, another 20 µl of EB buffer were added. The BAC DNA was allowed to 





2.2 Gel electrophoresis 
Gel electrophoresis is a method to separate DNA, RNA, or protein depending on their size. 
DNA and RNA are negatively charged and migrate in a matrix gel to the anode when placed 
in an electric field. The matrix gel is a polymerized network with small pores. Depending on 
their size, the molecules migrate with inverse velocities. For DNA and RNA agarose gels are 
used as matrix. Polyacrylamide is used for small DNA fragments and for the separation of 
proteins (2.7.5). 
2.2.1 Agarose gels 
Agarose is a non-toxic polysaccharide that is widely used for the separation of DNA. In 
general, agarose gels are used at percentages from 0.7-3 %. The agarose powder is dissolved 
in a buffer solution (TBE or TAE), containing ions to enable current flow and for stabilizing 
pH.  
 
TBE and TAE buffer 
Tris/borate (TBE) and Tris/acetat (TAE) buffer are the most commonly used buffers for 
agarose gel electrophoresis. The advantage of TBE is its higher buffer capacity (Voytas, 
2001), making it useful for high voltage electrophoresis over long time periods, like PFGE 
(2.2.3). A negative aspect of TBE is its low solubility in concentrated stock solutions. The 
maximal concentration of the stock solution is 10x and even at this concentration 
precipitation occurs. In contrast to this, the TAE buffer can be stored as a 50x buffer. For 
preparative gels, TAE is the preferred buffer because TBE can inhibit the binding of DNA to 
silica membranes (Moore et al., 2002).  
 
Ethidium bromide 
Ethidium bromide (EtBr) is still the most commonly used substance to detect DNA in agarose 
gels. It is an aromatic compound and shows an increased fluorescence when intercalated 
into DNA. Detection of DNA with EtBr is a sensitive assay, which has a detection limit of 
about 1-5 ng/band. Therefore, 0.3-0.8 µg/ml was added to the melted agarose before 








DNA solutions have mainly the same density as the electrophoresis buffer and second and 
they are usually clear solutions. Therefore, they cannot easily be loaded onto a gel without 
adding a loading buffer. The loading buffer contains glycerol or sucrose to increase the 
density so that the DNA sample sinks into the gel pocked. Additionally, the buffer contains a 
loading dye like bromophenol blue to make the solution visible and to simplify the 
observation of the gel run. Many loading buffers also contain EDTA to inhibit enzymes, like 
restriction enzymes or DNases. 
2.2.2 Gel extraction 
After separating restriction products with agarose gel electrophoresis, the bands of interest 
have to be isolated and purified. This can easily be done with the Gel Extraction kit (QIAprep 
Spin Miniprep Kit). The extraction was done accordingly to the manufacturer's protocol. The 
DNA fragment was excised from the agarose gel with a scalpel and weighed. 3 volumes of 
QG buffer were added and the gel slice was shaken at 50 °C for 10 min. For precipitation, 1 
volume of isopropanol was added to the completely dissolved gel slice solution and the 
mixture was loaded onto a column with a silica membrane. 
2.2.3 Pulsed field gel electrophoresis (PFGE) 
DNA fragments longer than 25 kb are difficult to separate by traditional agarose gel 
electrophoresis (Finney, 2001). Long fragments are twisted and need a lot time for re-
orientation to migrate through the agarose network. The time of re-orientation has a higher 
influence on the migration velocity than the size itself and this makes a separation by size 
almost impossible. One way to circumvent this problem is to change the current direction 
frequently. This method is called pulsed field gel electrophoresis (PFGE) and gives good 
results up to DNA sizes of 2000 kb. In contour-clamped homogeneous electric field (CHEF) 





Figure 7: Voltage clamping of the CHEF DRII 
System (taken from the instruction 
manual), showing the hexagon with the 





The CHEF DRII System from BioRad that was used has a hexagon structure with a maximal 
angle of 120 °. PFGE is usually run for long time periods and at high voltages. To reduce the 
heat production 0.5x TBE was used to lower the current. A recirculation system with a 
cooling unit was used to cool the buffer to 14 °C. The samples were run on a 1 % agarose gel 
at a voltage of 6 V/cm. The run time was 24 h with pulse parameters of 1-25 s. The gel was 
then stained for 45 min with EtBr. EtBr was not added before to the melted agarose because 
EtBr has been shown to slow down the re-orientation of the DNA. 
 
2.3 Polymerase chain reaction (PCR) 
The standard PCR is a method to produce millions of copies of a specific DNA sequence in a 
few hours. For PCR, only a small amount of DNA, an oligonucleotide primer pair, 
deoxyribonucleoside triphosphates (dNTPs), a thermostable DNA polymerase, and a 
thermocycler are required. The typical PCR program includes three steps: denaturation, 
annealing and elongation. During the denaturation, the DNA double strands are separated at 
high temperatures of about 95 °C. In the annealing step, the primers bind to the DNA. The 
hybridization temperature depends on the oligonucleotide sequence and length. The third 
step is the elongation phase, where the polymerase extends the primers at 72 °C, the 
optimal extension temperature for the polymerase. The steps are repeated 20-40 times 
(cycles). Over the last years the application area for PCR has increased tremendously. In the 
cloning procedure of Viaat-HA-cEPOR±IRES-Venus, PCR was used to create the 3' and 5' 
miniarms for the homologous recombination.  
2.3.1 Creation of the 3' miniarm  
The PCR can be used to insert new restriction sites into DNA sequences. For this purpose, 
oligonucleotide primers have to be designed with 5' overhangs carrying the new restriction 
sites. This technique was used in the creation of the 3' miniarm (Figure 8). 
 





Both primers, 20341 and 20342, were designed with overhangs and integrated 3 new 
restrictions sites (PacI, SpeI, NheI). For this, approximately 10 ng of the BAC RP23-392P11 
were amplified with 2.5 U Pfu polymerase in 1x cloned Pfu buffer, with 200 µM dNTPs and 
12.5 pmol of primer 20341 and 20342 in a total volume 50 µl. The PCR program started with 
an initial denaturation at 95 °C for 1 min. The amplification was carried out for 25 cycles 
including 45 s denaturation at 95 °C, 45 s annealing at 66 °C and 80 s elongation at 72 °C. 
After the final elongation for 10 min at 72 °C, 1 U REDTaq DNA Polymerase was added to the 
PCR mixture and incubated for 10 min at 72 °C. The REDTaq polymerase has a terminal 
transferase activity and adds single 3' overhanging adenosine nucleotides. This is needed for 
cloning the fragment into the TOPO vector (2.3.3).  
2.3.2 Creation of 5' miniarm  
The creation of the 5' miniarm included an introduction of a new restriction sites with primer 
20289 (SacI/EcoRI) and additionally used the method of an overlap extension PCR. The first 
step of an overlap extension PCR is the amplification of two separate fragments (Figure 9, 
PCR 1). Importantly, the 3' primer 20299 of fragment 1 (from template RP23-392P11) has an 
overhang, which is complementary to the 5' end of fragment 2 (from template HA-cEPOR). 
Approximately 10 ng of RP23-392P11 and alpha-CaMKII-HA-cEPOR were amplified with 2.5 U 
Pfu polymerase in 1x cloned Pfu buffer, with 200 µM dNTPs and 12.5 pmol primers in a 
volume of 50 µl. The PCR programs started with an initial denaturation at 95 °C for 1 min. 
The amplification was carried out for 25 cycles including 45 s denaturation at 95 °C, 45 s 
annealing at 66 °C for fragment 1, 45 s annealing at 57 °C for fragment 2, 80 s elongation for 
fragment 1 and 60 s elongation for fragment 2 at 72 °C. The PCR program ended with a final 
elongation for 10 min at 72 °C and a cool down to 12 °C. In the second PCR (Figure 9, PCR 2), 
the two fragments were put together. After denaturation, both fragments were fused 
through the overlapping sequence. Therefore, no primers were added and the Pfu 
polymerase was only filling in the 5' overhangs. For this, 2 µl of both PCRs reactions were 
mixed with 200 µM dNTPs, 2.5 U Pfu-polymerase in 1x cloned Pfu buffer in a volume of 
45 µl. The PCR program started again with an initial denaturation at 95 °C for 1 min, followed 
by only 5 cycles including 45 s denaturation at 95 °C, 45 s annealing at 57 °C, and 2.5 min 
elongation at 72 °C. The PCR program ended again with a final elongation for 10 min at 72 °C 
and a cool down to 12 °C. In a third step, the fusion product was amplified (Figure 9, PCR 3). 





mixture and run with the same PCR program as PCR 2, but with 20 cycles. As for the 
3' miniarm, single adenosine nucleotides were added with the REDTaq DNA polymerase to 
enable the TOPO cloning. 
 
 
Figure 9: Illustration of the creation of the 5'miniarm with PCR. 
 
2.3.3 Cloning of PCR products - TOPO TA Cloning Kit  
The classical way of cloning PCR products is to use primers with restrictions sites. After 
cutting the purified PCR product at the newly inserted restriction sites, it can be cloned into 
any vector with complementary restriction sites. This method has the disadvantage that 
some restriction enzymes cut with low affinity near the end of a fragment and that primers 
with the respective cutting sites need to be designed. An easier way of cloning PCR products 
is to use the TOPO TA cloning kit. This kit provides a vector cut with the vaccinia 
topoisomerase (cutting site CCCTT). The vector has two 5' overhangs with T (Figure 10). This 





produced by Taq polymerase. In contrast to the Pfu polymerase, which has a proofreading 
enzyme and creates blunt ends, the Taq polymerase has a terminal transferase activity and is 
adding single 3' overhanging adenosine nucleotides (as described above). 
 
 
Figure 10: Illustration of the pCRII TOPO cloning (from the instruction manual). 
 
 
According to the manufacturer's protocol, 1 µl of the 3' miniarm fragment or 4 µl of the 
fused 5' miniarm fragment were incubated with 1 µl of the TOPO-vector in a diluted salt 
solution for 5 min on ice. XL-1 Blue cells were transformed with the miniarm-TOPO-plasmid-
ligation mixture and analyzed for the correct plasmids. 
2.3.4 Purification of PCR products from PCR reactions  
The purification was done with the MSB Spin PCR Kit (Life Technologies). Following the 
manufacturer's protocol, 500 µl were added to 100 µl of the PCR sample and mixed by 
vortexing. The solution was transferred to the spin filter column and centrifuged for 1 min at 
11,000 rpm. The filtrate was removed and the column centrifuged for 2 min at 11,000 rpm. 
The spin filter was placed into a 1.5 ml tube and 15 µl EB buffer was added to the center of 
the spin filter. After incubation for 1 min, the PCR product was eluted with centrifugation at 





2.4 Genetic engineering (in vitro) 
The traditional genetic engineering uses restriction enzymes and DNA ligases to cut and re-
join DNA fragments (Copeland et al., 2001).  
A typical genetic engineering process is made up as follows:  
1.) The plasmid and insert are cut with restriction enzymes (2.4.1). 
2.) The DNA is separated and purified by gel electrophoresis and gel extraction (2.2.2).  
3.) The DNA can be blunt-ended if different restriction enzymes had to be used (2.4.2).  
4.) The vector is dephosphorylated (2.4.3).  
5.) The vector is ligated with the insert (2.4.4).  
6.) The ligated construct is transformed and amplified in E. coli (2.4.5).  
7.) The plasmid is isolated (2.1.1) and analyzed with a diagnostic restriction digest (2.4.6). 
8.) E. coli clones carrying the correct plasmids are frozen in glycerol stocks (2.4.8). 
2.4.1 Restriction enzymes  
Restriction enzymes are sequence specific endonucleases. They originate from bacteria and 
serve as a protective mechanism against viral infections by cutting foreign DNA (Berg JM, 
2002). There are several types of restriction enzymes which differ in the number of subunits, 
cofactor requirements, and the distance between recognition and cutting site (Bickle and 
Kruger, 1993). Type II restriction enzymes are the simplest ones and are mainly used for 
genetic engineering. They recognize and cleave DNA at the same sequence and need only 
Mg2+ as a cofactor. The recognition site is usually 4-8 nucleotides in length and is 
palindromic.  
In general, 3-7 µg of vector and insert were cut with approximately 10 U enzyme per 1 µg 
DNA. The reactions were carried out in the recommended buffer with the addition of 
100 µg/ml BSA in a total volume of 100 µl and incubated at 37 °C for 2-4 h. The digestion was 
stopped by adding the loading buffer/stop mix.  
2.4.2 Fill-in with Pfu (creation of blunt ends) 
The creation of blunt ends is helpful for ligating DNA fragments after restriction digestion 
with different enzymes. The Pfu polymerase is a 5'-3' polymerase with a high heat-stability 
(half-life of 12 h at 95 °C) and a 3'-5' exonuclease activity (proofreading). Additionally, the 
polymerase is able to remove 3' overhangs (polishing) and to fill-in 5' overhangs, which 





200 µM dNTPs and 70 µl of the purified restriction fragments. The reaction mix of 100 µl was 
incubated for 30 min at 72 °C.  
2.4.3 Dephosphorylation of the vector 
The ability of self-ligation (re-ligation) of linearized vectors prevents the integration of 
inserts during in the ligation reaction. This can be reduced by dephosphorylation of 5' ends 
of the vector, catalyzed by alkaline phosphatases. According to the manufacturer's protocol 
the vector DNA was dephosphorylated with 1 U of rAPid alkaline phosphatase, 1x rAPid 
alkaline phosphatase buffer in a volume of 20 µl for 10 min at 37 °C. The alkaline 
phosphatase was inactivated by heating for 2 min at 75 °C.  
2.4.4 Ligation of vector and insert 
DNA ligases catalyzes the formation of a phosphodiester bond between a free 3' hydroxyl 
group of one DNA strand and a free 5' phosphate group of another DNA strand (Berg JM, 
2002). This reaction is frequently used in traditional engineering. The reaction was 
performed according to the manufacturer's protocol with minor modification. Vector and 
insert were ligated with 2 U of T4 ligase in a volume of 20 µl overnight at 0-24 °C. The 
concentration of vector and insert was approximately 10-200 ng with a 3-fold molar excess 
of insert. The ligation product was immediately transformed into E. coli or stored at -20 °C. 
2.4.5 Transformation 
Electroporation is one of the most efficient ways to transform plasmid DNA into E. coli cells. 
It is recommended to work close to a Bunsen flame to avoid contamination. Electroporation 
cuvettes and E. coli cells were cooled on ice before transformation. For the transformation 
1 µl of the ligation mix was added to 50 µl E. coli cells. The cell suspension was transferred 
into an electroporation cuvette (1 mm gap width) and electroporated at 1.8 kV. Afterwards 
1 ml LB medium was added to the cell suspension and the mixture was transferred into a 
1.5 ml reaction tube. The cells were incubated for 1 h at 37 °C. After the recovery phase, the 
cells were centrifuged for 30 s at 13,000 rpm. The supernatant was discarded and the cells 
were plated in approximately 50 µl on pre-warmed selective agar plates and incubated 





2.4.6 Diagnostic restriction digest  
Usually, 12 clones were picked from the agar plates and grown in 5 ml selective LB medium 
overnight at 37 °C. For a the diagnostic restriction digest, 1.5 ml of the overnight culture was 
used for the plasmid isolation (2.1.1) and 5 µl of the isolated plasmid DNA were digested 
with 0.5 µl of the restriction enzyme, 0.5 µl RNase A (10 µg/µl) and 5 µl BSA (10 µg/µl) in the 
recommended buffer, in a total volume of 50 µl, at 37 °C for 2 h. The restriction digest was 
analyzed after gel electrophoresis (2.2.1). 
2.4.7 Bacterial culture medium 
Bacterial cultures are relatively easy to grow. The most commonly used medium is Luria 
Broth (LB) medium. It contains 10 g tryptone, 5 g yeast extract and 10 g NaCl per liter. For 
liquid LB medium 25 g of LB powder was dissolved in 1 l ddH2O. To obtain solid LB medium, 
15 g Bacto-Agar was added per liter. The medium was autoclaved at 121 °C for 20 min, 
cooled down to approximately 60 °C, and antibiotics as selective growth compounds were 
added. The antibiotic concentrations used were 50 µg/ml ampicillin (Amp), 25 µg/ml 
kanamycin (Kan) and 12.5 µg/ml chloramphenicol (Chl). Warm solid LB medium was poured 
into petri dishes (approximately 20 ml per dish) to obtain selective agar plates.  
2.4.8 Glycerol stocks 
Glycerol is used as cryoprotectant for long-term storage of bacterial cells. For this purpose, 
85 % glycerol solution was diluted in LB medium to 30 % (3.5 ml of glycerol 6.5 ml 
LB medium) and mixed 1:1 with the bacterial overnight culture (750 µl 30 % glycerol solution 
and 750 % bacterial culture). The bacterial-glycerol solution is mixed by pipetting and frozen 
at -80 °C in 2 ml cryo tubes. Glycerol stocks stored at -80 °C are stable over many years. 
 
2.5 Recombineering 
Generation of BAC transgenic animals needs modern tools of genetic engineering. 
Recombineering is an in vivo method of genetic engineering based on homologous 
recombination (recombinogenic engineering) (Copeland et al., 2001; Sawitzke et al., 2007; 
Sharan et al., 2009). The method was originally used for chromosome engineering of 
Saccharomyces cerevisiae (yeast) (Baudin et al., 1993) and in contrast to the traditional in 





is a big advantage for the creation of transgenic mouse models using large vectors like 
bacterial artificial chromosomes (BACs). Modifying a BAC with the traditional genetic 
engineering is almost impossible because of the difficulties in finding unique restriction sites. 
This makes the recombineering technique indispensable and promoted the development of 
the method over the last years. One issue was that linear dsDNA is unstable in E. coli due to 
an exonuclease (RecBCD). This could be circumvented, for example with mutated forms of 
RecBCD or degradation-preventing sequences (Chi sites) at the ends of the linear DNA. Over 
the years two phage-encoded recombination systems with high efficacies were developed. 
One uses the RecE/RecT proteins from Rac prophage, the other the Redαβγ proteins from 
bacteriophage λ. 
2.5.1 Bacteriophage λ recombination system 
The bacteriophage λ system uses the phage 
recombination proteins exo, bet and gam. The 
Gam protein inhibits the nuclease activity of 
RecBCD and stabilizes the linear dsDNA. The Exo 
protein is a 5'-3' exonuclease, binds to the 5' end 
of linear dsDNA and produces 3' overhangs 
(Figure 11). Protein Beta binds to 3' ssDNA, 
promotes the annealing to the complementary 
strand and generates recombinant DNA.  
 
Figure 11: Schematic illustration of the bacteriophage λ 
recombination system (from Sharan et al., 2009). 
 
2.5.2 Defective λ-prophage-based system 
Two bacteriophage λ derived constructs used for recombination are shown in Figure 12. The 
red genes exo, bet and gam are located in the PL operon. Additionally, N, kil, xis and int are 
located in this transcriptional unit. The N protein is an anti-terminator for the termination 
sites tL1tL2 and tL3, needed for the complete transcription of the PL operon genes. Xis and 
Int are proteins originally necessary for the excision and integration of the phage DNA, 
whereas the attachment sites (att) are complementary to the bacterial genome and navigate 
the integration of the phage DNA in between the galactose and biotin operon of the E. coli 





and release of the virus particle. This is why the timing and expression level of the genes are 
critical in using the system for recombineering. A temperature-sensitive mutation cI857 
assists to circumvent this issue (Defective λ-prophage-based system). The repressor CI857 is 
stable at 32-37 °C but degrades with a temperature shift to 42 °C. Thus, the expression of 
the genes can be easily regulated by the cultivation temperature.  
The second operon is the replication operon PR and harbors the genes cro, OP, Q, SRA-J. OP 
are replication genes, the Cro protein can partially repress the transcription of PL and PR 
when CI857 is inactive. Q is the regulator of the lysis and structural genes SRA-J. The 
replication operon PR is not needed for recombination and was deleted in some 
recombinogenic bacterial strains (Figure 12b). In addition, the attachment site was deleted. 
This has the advantage that the prophage has neither the ability for excision nor replication. 
 
 
Figure 12: Schematic representation of the bacteriophage λ construct used for recombination (from Sharan 
et al., 2009). (a) The phage DNA (red) is flanked by attachment sites (att). The integration of the phage takes 
place in between the galactose and biotin operon (bioAB) of the bacterium genome (blue). The PL operon (pL) 
contains genes for the anti-terminator (N), the killing gene (kil), the recombinogenic genes (exo, bet, gam) and 
the excision and integration genes (int, xis). The replication operon (pR) contains a repressor gene (cro), the 
replication genes (OP), a regulator gene (Q) and structural genes (SRA-J). The mutated repressor gene (cI857) 
leads to temperature regulated transcription of the PL and PR operon. (b) The replication operon (PR) and the 
attachment sites (att) are deleted from the bacteriophage λ construct, preventing the excision and replication 
of the prophage. 
 
2.5.3 Recombinogenic strain - SW105 
SW105 is one of the newest E. coli recombinogenic strains and was used in the current 
study. It is derived from EL250, which itself is a derivate of DY380, the first recombinogenic 
strain derived from the parent strain DH10B. In SW105, the PR operon and the attachment 
sites are deleted (Figure 12b), preventing excision and replication of the prophage. The 
strain carries an additional araC inducible flpe gene (araC-PBAD Flpe). This allows the excision 





2.5.4 Generation of electrocompetent SW105 
SW105 cells were grown overnight in 5 ml LB medium at 32 °C (no expression of 
recombineering genes). 3 ml of the overnight culture were used to inoculate 60 ml 
LB medium. The cells were grown to an OD600 of 0.5-0.6. The flasks were cooled down in ice 
water. The cell suspension was transferred into 8 prechilled 15 ml Falcon tubes. The cells 
were washed 3 times with ice-cold water. For this, the cell suspension was centrifuged for 
10 min at 3,500 rpm at 0 °C and the pellet was resuspended in ice-cold water on a rotating 
wheel in a 4 °C cold room. After three rounds of washing, the pellet was resuspended in 
100 µl water, distributed in 2x 1.5 ml reaction tubes and placed on ice. 
2.5.5 Transformation of the BAC into the recombinogenic strain SW105 
In the next step, the Viaat-BAC RP23-392P11 (which carries a chloramphenicol resistance) 
was transformed into the recombinogenic strain, SW105. Therefore, the BAC DNA was 
isolated (2.1.3) and 1 µl of the isolated BAC DNA was used for the transformation of the 
freshly generated electrocompetent SW105 cells. The transformed bacteria were plated on 
LB/Chl agar plates for 16-24 h at 32 °C. Four colonies were picked, transferred into 6 ml 
LB/Chl medium, and were grown overnight at 32 °C. Glycerol stocks were generated with 
750 µl of the overnight culture (2.4.8). The BAC DNA was isolated for diagnostic restriction 
digestion (2.4.6) with PacI and PmeI. For this purpose, 10 µl BAC DNA was cut with 15 U PacI 
or PmeI in the recommended buffer in a reaction volume of 50 µl for 16 h at 37 °C. The 
correct fragment size was confirmed by PFGE (2.2.3). 
2.5.6 Recombineering 
BAC RP23-392P11 containing SW105 cells were grown at 32 °C in 60 ml LB/Chl medium. 
When the cells reached an OD600 of 0.5-0.6, the expression of the recombineering genes was 
induced by incubating the cells for 15 min at 42 °C, followed by cooling Afterwards the cell 
suspension was cooled down on ice. The cells were made electrocompetent (2.5.4) and 1 µl 
(120-165 ng) of the linearized purified constructs (which carry an ampicillin resistance) were 
used for electroporation. The cells were allowed to recover at 32 °C for 1 h and plated on 
LB/Chl/Amp agar plates. Cells which have integrated the linearized construct by homologous 






Figure 13: Illustration of the homologous recombination in cloning step 10. 
 
2.5.7 Flpe/FRT recombination system and excision of AmpR 
The Flpe/FRT recombination system mechanism was used in the cloning procedure for the 
excision of the AmpR gene and is therefore explained in more detail. The arabinose operon 
allows E. coli to grow on L-arabinose. The operon is controlled by the repressor protein AraC, 
which inhibits the transcription of the arabinose genes if no L-arabinose is present. In the 
recombinogenic stain SW105, the Flpe gene (derived from Saccharomyces cerevisiae) is 
inserted behind the pBAD promoter of the arabinose operon (Figure 14). Without L-arabinose, 
the dimeric AraC protein binds in two separate DNA regions creating a DNA loop (Schleif, 
2003). In this configuration, the RNA polymerase cannot bind the pBAD promoter (Figure 





DNA sites, allowing the transcription of the Flpe gene. The Flpe gene codes for a flippase, 
which recombines at defined target sites, termed FRT (Branda and Dymecki, 2004; Lacroix et 
al., 2011). Flpe excises DNA located between two FRT sites having the same orientation 
(Figure 14B). This mechanism was used to excise the AmpR gene in cloning step 11. 
 
Figure 14: Illustration demonstrating the L-arabinose induced excision of DNA with the site specific FLpe/FRT 
recombination system. (A) L-arabinose induced expression of Flpe (adapted from Schleif, 2003) (B) Flpe 
induced excision of the AmpR.  
 
Therefore, 5 ml overnight cultures of Viaat-HA-cEPOR-frtAmpRfrt and HA-cEPOR-IRES-Venus-
frtAmpRfrt were used to inoculate 250 ml selective LB/Chl medium. The cells were grown to 
an OD600 = 0.4 before 2.5 ml 10 % arabinose solution were added. The cells were shaken for 
1 h at 32 °C. 10 µl of an 1:1000 dilution were plated on LB/Chl agar plates. Two clones were 










2.6 Linearization of the BAC and pronuclear injection 
2.6.1 Linearization of the BAC 
The BAC Viaat-HA-EPOR and Viaat-HA-EPOR-IRES-Venus were amplified in 250 ml LB/Chl 
medium and the BAC DNA was isolated with BAC maxi preparation (2.1.3). NruI was used to 
cut out the backbone pBAC3.6 and to linearize the BAC constructs. For this, 24 µg of BAC 
DNA were digested with 70 U NruI with BSA in a total volume of 100 µl overnight at 37 °C. 
The next day, the digest was purified by a self-made sepharose-column. A 5 ml plastic 
pipette served as the column. The cotton plug from the top of the pipette was pushed to the 
narrow end and the top part was cut off at the -1 mark. The pipette was mounted in a ring-
stand and CL-4B sepharose was diluted 1:4 with injection buffer and was filled into the 
pipette up to the 5.5 ml mark. A 10 ml syringe (with plunger removed) was mounted on top 
of the pipette and sealed with Parafilm. The column was equilibrated 2 times with 10 ml 
injection buffer. The volume of the digest was adjusted to 200 µl and mixed with 5 µl 0.25 % 
bromophenol blue. The sample was loaded to the column. After the sample entered the 
bedding, 5 ml of injection buffer was added and fractions of approximately 200 µl (3 drops) 
were collected. For quality control, 25 µl of the fractions with the highest amount of DNA 
were separated by PFGE. The selected fraction was diluted to 1 ng/µl with injection buffer 
for microinjection. 
2.6.2 Pronuclear injection 
The microinjection was done in the animal facility of the Max Planck Institute of 
Experimental Medicine under the direction of Dr. Ursula Fünfschilling. The microinjection 
was performed on 6 days per construct, Viaat-HA-EPOR and Viaat-HA-EPOR-IRES-Venus 
(Table 2). On each day approximately 150 fertilized eggs (of 15 superovulated bred 
C57BL/6N females, day 0.5) were isolated and injected. Injected eggs appearing vital were 
re-implanted into the oviducts of 
pseudopregnant females (foster 
mothers). The offspring was genotyped 
to identify transgenic animals. 
 
Table 2: Table presenting the construct 
injections dates, the number of the vital 
appearing injected pronuclei and number of 















Methods Part II 
2.7 Analysis of the transgenic mouse 
2.7.1 PCR-based genotyping 
 
Isolation of DNA from tail biopsies 
The DNA for the genotyping was isolated from tail biopsies of 2-3 week old mice with the 
NucleoSpin Tissue Kit. For lysis, the mouse tails were incubated in 180 µl T1 buffer with 25 µl 
Proteinase K for at least 3 h at 56 °C. The lysate was vortexed after addition of 200 µl buffer 
B3 and 210 µl ethanol and transferred to a silica column. After centrifugation at 11,000 rpm 
for 1 min at RT, the column was washed with 500 µl buffer BW and 600 µl buffer B5. The 
membrane was dried by centrifugation at 11,000 rpm for 1 min and the DNA was eluted with 
100 µl pre-warmed (70 °C) BE buffer.  
 
Genotyping-PCR (Viaat HA-cEPOR±IRES-Venus) 
The genotyping for the identification of the founders was done by PCR with one primer pair 
binding in the polyA sequence of the construct (25763/25764) and another primer pair 
binding in the gene of Interleukin 2 (5063/5064), which was used as endogenous control. 
The founder animals were further genotyped with three other primer pairs located in 
different regions of the construct (26857/26958, 2521/24016, 26859/26860). In all PCRs, 1 µl 
of the isolated DNA from tail biopsies was amplified using 1 U REDTaq polymerase in 
1xREDTaq buffer, with 125 µM dNTPs and 250 nM primers in a volume of 20 µl. The PCR 
program started with an initial denaturation at 95 °C for 1 min. The amplification was carried 
out for 32 cycles including 45 s denaturation at 95 °C, 45 s annealing at 58 °C and 45 s 
elongation at 72 °C. After the final elongation for 7 min at 72 °C, the PCR mixture was cooled 
down to 4 °C. The PCR samples were run on a 2 % agarose gel at 120 V for 45 min. 
2.7.2 Immunohistochemistry 
The analysis of the construct expression was done with fluorescent immunohistochemistry. 
Young animals of 4-6 weeks were perfused and stained with antibodies against the HA-tag 





Perfusion, cutting and storage of brain tissue 
To achieve a sufficient fixation and good preservation of the brain tissue (Zeller, 2001), the 
animals were transcardially perfused with 4 % formaldehyde (FA). Therefore the mouse was 
anesthetized by intraperitoneal injection with 0.276mg/g Avertin. Before opening the 
thorax, the mouse was tested to be negative for reflexes in the hind paw. Then, the rib cage 
was carefully cut and the diaphragm removed to get access to the heart. A butterfly needle 
connected to the running peristaltic pump was inserted into the left ventricle and right 
atrium was cut open. Blood was flushed out with cold Ringer solution for approximately 
1 min, before the solution was switched to the cold 4 % FA solution for fixation. After 4 min 
perfusion with 4 % FA, the brain was dissected and postfixated for 24 h in 4 % FA at 4 °C. The 
brains were placed for 2 days in a 30 % sucrose solution for dehydration and frozen in liquid 
nitrogen. Afterwards, they were stored at -80 °C until cutting. The brains were embedded in 
Tissue-Tek, cut into 30 µm thick coronal sections on a cryostat, and stored in an ethylene 
glycol based cryoprotectant solution at -20 °C (Watson et al., 1986). 
 
Immunofluorescence staining 
There are several immunofluorescent staining methods, which differ in their sensitivity. In 
the simplest staining, the primary antibody is directly conjugated with the fluorescent dye 
(Figure 15A). The advantages of direct labeling are the shorter staining times and a reduced 
risk of cross reactivity. This can be very helpful in multiple staining, where antibodies are 
raised in the same species. But direct fluorescent labeling has the lowest sensitivity and, in 
general, is only successful if the antigen is present in very large amounts. The most 
commonly used method is the indirect labeling, where the secondary antibody is labeled 
with a fluorophore (Figure 15B). The method shows a higher sensitivity compared to the 
direct fluorescent labeling, but the combination of antibodies has to be planned thoroughly, 
especially in multiple staining to avoid cross reactivity. An enhanced staining method with an 
even higher sensitivity uses the streptavidin-biotin system. In this method, fluorescently 
labeled streptavidin molecules bind with high affinity to the biotin labeled secondary 
antibody (Figure 15C). Another method, which has a tremendously high sensitivity, combines 
the avidin-biotin complex (ABC) technique with the tyramide signal amplification (TSA) 
(Figure 15D). The staining starts with a biotin labeled secondary antibody. In the next step, 





biotin labeled tyramine into a reactive free radical, which binds covalently to surrounding 
protein molecules. In the last step, a fluorescently labeled streptavidin binds to biotin. This 
method includes many steps and is time consuming and expensive, but in some cases it is 
the only option to receive a good staining result. The dimensions of amplification are 
illustrated in Figure 15D. 
 
Figure 15: Illustration of different immunofluorescent staining methods. (A) Direct fluorescent staining 
method. (B) Indirect fluorescent staining method. (C) Biotin-streptavidin enhanced indirect fluorescent staining 
method. (D) ABC and TSA enhanced indirect fluorescent staining method. Primary antibody (black), secondary 
antibody (dark blue), B=Biotin, S=Streptavidin, A= Avidin, HRP=Horseradish peroxidase, T=Tyramine.  
 
Testing single staining of the HA-tag and IRES-Venus 
The coronal brain sections, which were stored in ethylene glycol based cryoprotectant 
solution at -20 °C, were washed 3 times for 15 min in 1x PBS at RT. The brain sections were 
mounted on superfrost ultra plus slides and dried overnight. The next day the sections were 
rehydrated for 5 min in ddH2O. The sections were cooked 3 times for 2 min in citrate buffer. 
They were cooled down for 5 min in ddH2O and washed 3 times in 1x PBS. Afterwards they 
were incubated in 0.5 % H2O2 for 30 min to inactivate endogenous peroxidases and washed 
again 3 times for 15 min with 1x PBS. Then, the sections were blocked with 5 % normal horse 





with 1:500 monoclonal rabbit anti-HA-tag (Cell Signaling) or 1:500 polyclonal anti-GFP (SYSY) 
antibodies in 3 % NHS, 0.5 % TritonX-100 in 1x PBS at 4 °C. After 3 days, the slides were 
washed 10 times for 6 min with 1x PBS. The sections were split into 3 groups to test 3 
different staining methods. Group 1 was incubated for 2 h at RT with the AlexaFluor488- 
conjugated donkey anti-rabbit secondary antibody at a concentration of 1:500 in 3 % NHS, 
0.5 % TritonX-100 in 1x PBS. Group 2 was first incubated with the biotinylated goat anti-
rabbit antibody with a concentration of 1:500 for 1 h at RT. The sections were washed 8 
times for 6 min with 1x PBS, and AlexaFluor488-conjugated streptavidin antibody was added 
and incubated for 2 h at RT. Group 3 was also incubated with the biotinylated goat anti-
rabbit antibody at a concentration of 1:500 for 1 h at RT, and was washed 8 times for 6 min 
with 1x PBS. In contrast to group 2, the ABC solution was added afterwards. Therefore, 
11.25 µl of solution A was mixed with 11.25 µl solution B in 10 ml 1x PBS and pre-incubated 
for 30 min at RT for ABC complex formation. The sections were incubated with 100 µl/ 
section for 45 min at RT. The sections were then washed again 3 times for 5 min and 
50 µl/section of the TSA solution (biotinylated tyramide stock solution dissolved 1:50 in the 
amplification diluent) were added. After incubated for 20 min, the sections were rinsed 
again 8 times for 6 min and AlexaFluor488-conjugated streptavidin was added and incubated 
for 2 h at RT at a concentration of 1:500 in 3 % NHS, 0.5 % TritonX-100 in 1x PBS. The 
sections of all groups were washed twice for 15 min with 1x PBS and the sections were 
stained with 100 µl/section 125ng/ml DAPI solution for 5 min. After 3 more washing steps 
for 15 min with 1x PBS, the sections were dried overnight and mounted with Aqua-
Poly/Mount the next day. The fluorescently stained sections were stored in the dark at 4 °C 
before imaging. 
 
Double staining of HA-tag and parvalbumin 
The sections were washed, cooked, pre-treated with H2O2, and blocked as described for the 
single staining test. Then, the sections were incubated for 72 h with 1:500 monoclonal rabbit 
anti-HA-tag and 1:2000 monoclonal mouse anti-parvalbumin antibody in 3 % NHS, 0.5 % 
Triton X-100 in 1x PBS at 4 °C. After 3 days the slides were washed 10 times for 6 min with 1x 
PBS. The biotinylated goat anti-rabbit antibody was applied at a dilution of 1:500 for 1 h at 
RT followed by 8 times washing for 6 min with 1x PBS. For the ABC complex, 11.25 µl of 
solution A was mixed with 11.25 µl of solution B in 10 ml 1x PBS and was incubated for 





for 45 min at RT. The sections were washed again 3 times for 5 min and 50 µl of the TSA 
solution (biotinylated tyramide stock solution dissolved 1:50 in the amplification diluent) 
were added per section and incubated for 20 min. The sections were rinsed again 8 times 
with 1x PBS for 6 min and AlexaFluor633-conjugated streptavidin and AlexaFluor488-
conjugated goat anti-mouse antibody were added in a concentration of 1:500 in 3 % NHS, 
0.5 % Triton X-100 in 1x PBS and incubated for 2 h at RT. The sections were washed twice for 
15 min with 1x PBS and the sections were stained 100 µl/section 125 ng/ml DAPI solution for 
5 min. After washing 3 times for 15 min with 1x PBS, the sections were dried overnight and 
mounted with Aqua-Poly/Mount the next day. The fluorescently stained sections were 
stored in the dark at 4 °C before imaging. 
2.7.3 Microscopy 
Images were obtained using an inverted light microscope (Leica DMI 6000B) with a 20x 
(single staining) or 40x (double staining) air objective. Pictures were processed using Fiji 
software. 
2.7.4 Quantitative real-time PCR (qPCR) 
In many studies, the amount or change in gene expression is of major interest. The 
expression can be measured at the level of transcription (mRNA) or translation (protein). 
Both, transcription as well as translation can be influenced by specific treatments or the 
integration of the transgene. Today, the most commonly used method to measure the level 
of transcription is quantitative real-time PCR (qPCR). 
 
RNA isolation 
The method used in the current work to isolate RNA was published as early as in 1987 by 
Chomczynski and Sacchi (Chomczynski and Sacchi, 1987; Chomczynski and Sacchi, 2006). 
They showed that RNA can be isolated in a single-step using an acid guanidinium 
thiocyanate-phenol-chloroform mixture. Only the RNA accumulates in the acidic aqueous 
upper phase after centrifugation at 12,000 xg. Genomic DNA accumulates in the interphase 
and proteins are located in the interphase and the organic phase. Conveniently, RNA 
isolation kits are used, which include TRIzol (Invitrogen) or QIAzol (Qiazol) reagent, which 





In this study, 6 week old mice were anesthetized by intraperitoneal injection with 
0.276 mg/g Avertin and sacrificed. Hippocampus (HP), cortex (CX) and cerebellum (CB) were 
dissected, immediately frozen on dry ice, and stored at -80 °C until further processing. RNA 
isolation was done with the miRNeasy Mini Kit from Qiagen accordingly to the 
manufacturer's protocol. HP, CX and CB were homogenized on ice with a polytron PT 1200E 
tissue homogenizer in 700 µl QIAzol. The cell lysate was further homogenized by passing 
through a syringe with a 27G needle twice. The samples were then incubated for 5 min at RT 
and 140 µl of chloroform were added. The samples were vortexed for approximately 15 s 
and then centrifuged at 12,000 rpm at 4 °C for 15 min. The aqueous phase was transferred 
into a new reaction tube and mixed with 1.5 volumes of 100 % ethanol. The mixture was 
loaded onto a miRNeasy Mini column and centrifuged for 15 s at 8,000 rpm at RT. The 
column was washed once with 700 µl RWT buffer and twice with 500 µl RPE buffer. The 
column was dried by centrifugation at 14,500 rpm for 1 min. The RNA was eluted with 50 µl 
RNase free water at 8,000 rpm for 1 min at RT. The RNA concentration was measured 
spectrophotometrically with a dilution of 1:25 in EB buffer at 260 nm in a quartz cuvette 
with a path of 1 cm. The ratio of the optical density (OD) of 260/280 nm was additionally 
analyzed to confirm the purity of the RNA (the optimal range is 1.8-2.0).  
 
Reverse transcription (cDNA) 
Next, the RNA was transcribed into cDNA. 1 µg of the isolated total RNA was incubated with 
120 pmol N9 random primers and 0.6 pmol anchored oligo(dT) primers (N23VN) in a volume 
of 12 µl for 2 min at 70 °C. Then, 8 µl of the master mix, consisting of 1 µl 200 U/µl 
SuperScript III, 4 µl 5x first strand buffer, 2 µl 0.1 M DTT and 1 µl 10 mM dNTPs, were added. 
The reaction was incubated for 10 min at 25 °C, 45 min at 50 °C, and 45 min at 55 °C. The 
samples were cooled down, diluted 1:10 with ddH2O and stored at -20 °C until usage. 
 
Quantitative real-time PCR (qPCR) 
qPCR is the method of choice to quantify gene expression on transcriptional level. The 
method was invented in 1991 and Higuchi and colleagues published a paper about the 
simultaneous amplification and detection of DNA during PCR in 1992 (Higuchi et al., 1992). 
By using fluorescent dyes, the PCR can be monitored in real time. Initially, EtBr was used as 
fluorescent dye. EtBr increases its fluorescence when intercalated into double-stranded 





such as SYBR Green. To analyze the expression level of EPOR in wt and transgenic animals, 
4 µl of the diluted cDNA was mixed with 5 µl 2x SYBR Green and 1 pmol primers (EPOR 
11329, 11330 or GAPDH 6038, 6039) in a total volume of 10 µl. The cDNA and the master 
mix were pipetted into 384 well plates aided by the epmotion robot 7075. Cycling and 
detections was done using a LightCycler 480 system. The initiation was done for 2 min at 
50 °C, followed by denaturation at 95 °C for 10 min. The amplification consisted of 45 cycles 
of 95 °C for 15 s and 60 °C for 60 s. The relative concentrations of EPOR mRNA were 
determined from three replicates using the cycle threshold (CT) method. The CT values of 
EPOR were normalized to the CT values of GAPDH. The specificity of the primer pairs was 
controlled by melting curve analysis.  
2.7.5 Western blot (WB) 
Similar as for the RNA isolation, 6 week old mice were anesthetized by intraperitoneally 
injection with 0.276 mg/g Avertin and sacrificed. Hippocampus (HP), cortex (CX) and 
cerebellum (CB) were dissected, immediately frozen on dry ice, and stored at -80 °C until 
further processing.  
 
Protein extraction 
For the analysis of the transgene cEPOR expression in the brain, the brain samples were 
homogenized on ice using a polytron PT 1200E tissue homogenizer in 300 µl phosphosafe 
buffer, containing 1 mM phenylmethylsulfonyl fluoride, 10 µg/ml aprotinin and 1 mg/ml 
leupeptin. The tissue lysates were further homogenized by pulling through a syringe with a 
21G needle 10 times and centrifugation at 12,000 rpm for 45 min. The supernatant was 
transferred into a reaction tube. Approximately 15 µl of the supernatant were stored in a 
separate reaction tube for measuring protein concentration. The remaining supernatant was 
mixed with 4x Laemmli buffer (1/3 of the supernatant volume). The protein samples were 
denatured for 5 min at 95 °C and stored at -80 °C. 
 
Protein measurement (Lowry) 
The concentration of protein was measured with the method of Lowry (Lowry et al., 1951). 
The HP protein samples were diluted 1:100 and the CX and CB protein samples were diluted 
1:200 in a total volume of 200 µl. In parallel, the dilutions for the standard curve were 





Afterwards 1 ml of a fresh copper solution was added to all samples, protein and standard 
curve samples. The mixtures were vortexed and incubated for 15 min. Then, 100 µl of Folin-
Ciocalteu reagent were added and the samples were vortexed immediately. After incubation 
of 45 min, the absorbance at 595 nm was measured in triplicates of 200 µl/well in a 96-well 
plate. The concentrations were calculated from the standard curve.  
 
Sodium dodecyl sulfate - polyacrylamide gel electrophoresis (SDS-PAGE) 
Gel electrophoresis is a method to separate DNA, RNA, or protein depending on their size. 
The separation of DNA and RNA is described in 2.2.1. The separation of protein is based on 
the same principles. Negatively charged proteins migrate in a matrix gel to the anode when 
placed in an electric field. In this case, polyacrylamide is used for the polymer network. The 
size of the pores can be regulated through the percentage of polyacrylamide. It is generally 
recommended to use 4-5 % gels for protein > 250 kDa, 7.5 % gels for proteins of 250-
120 kDa, 10 % gels for proteins of 120-40 kDa, 13 % gels for proteins of 40-15 kDa and 15 % 
gels for proteins < 20 kDa. In contrast to DNA and RNA, proteins are not uniformly charged, 
because of their varying amino acid composition. Therefore, they are not separated 
depending to their size in a native PAGE. By the addition of the detergent SDS that covers 
the protein with a total negative charge, the proteins can be separated according to their 
size (Kurien and Scofield, 2006; Laemmli, 1970). After separation (Figure 16A), the proteins 
are blotted onto an absorbent membrane (Figure 16B), where the protein of interest can be 
detected and visualized with antibodies (Figure 16C-E). 
 





The used acrylamide percentage for separating the proteins of EPOR (70 kDa) and GAPDH 
(36 kDa) was 12 %. For the stacking gel, 15 ml of 30 % acrylamide, 9.77 ml of the lower 
buffer and 13.13 ml ddH2O was mixed and 125 µl of a freshly prepared 10 % APS solution 
and 30 µl of TEMED were added. The solution was briefly mixed and immediately filled into 4 
glass plate sandwiches (width: 1.0 mm). After 30 min, the stacking gel was prepared: 1.3 ml 
of 30 % acrylamide, 2.5 ml of the upper buffer, and 6.1 ml ddH2O were mixed and 50 µl of a 
freshly prepared 10 % APS solution and 10 µl of TEMED were added. The solution was briefly 
mixed and poured on top of the running gel and a comb for 10 pockets was inserted. After 
approximately 1 h, the gels were placed into the electrode assembly and the chamber was 
filled with 1x running buffer. The combs were removed and 50 µg of the protein samples 
were loaded for each lane. In one lane, 5 µl of a protein ladder was run as a size control. The 
gel was run for 15 min at 80 V and approximately 1.5 h at 120 V until the ladder reached the 
bottom of the gel. The proteins were then transferred onto a nitrocellulose membrane for 
2 h at 235 mA. The membranes were blocked for 1 h in 5 % milk in Tris buffered saline with 
0.05 % Tween (TBST). The membranes were incubated with rat anti-HA (1:250) overnight at 
4 °C. The next day, the membranes were washed 3 times for 15 min with TBST and incubated 
with the secondary HRP-coupled anti-rat antibody (1:2500) for 1 h at RT. After washing 3 
times for 15 min with TBST, the membranes were incubated with 2 ml of chemiluminescent 
substrate for 5 min at RT. The bands were visualized on a photographic film. Afterwards, the 
membranes were incubated with stripping buffer for 1 h at RT to remove the bound 
antibodies and washed 3 times for 15 min with TBST. The membranes were then blocked 
again for 1 h with 5 % milk in TBST at RT followed by incubation with mouse anti-GAPDH 
(1:5000) overnight at 4 °C. The next day, the membranes were washed 3 times for 15 min 
with TBST and incubated with the secondary HRP-coupled anti-mouse antibody (1:5000) for 
1 h at RT. After washing 3 times for 15 min with TBST, the membranes were finally incubated 
with 2 ml of chemiluminescent substrate for 5 min at RT. The bands were visualized on a 
photographic film. The protein bands of HA and GAPDH were densitometrically analyzed 
using the Fiji software and the HA values were normalized to the values of GAPDH.  
2.7.6 Hematocrit 
For measuring the hematocrit, the mice were anesthetized by intraperitoneal injection with 
0.276 mg/g Avertin solution. The blood was removed with a syringe directly from the left 





transferred into micro hematocrit capillaries and centrifuged for 10 min at 8,000 rpm. The 
percentage of erythrocytes was analyzed with a micro hematocrit reader. 
2.7.7 Behavior analysis 
The behavioral experiments have been performed in the Clinical Neuroscience Behavior Unit 
by Daniela Winkler. For all experiments, male and female Viaat-HA-cEPOR mice, strain D14-
0023, and wildtype (wt) C57BL/6N mice (littermates) of the second generation were used. 
All experiments were approved by the local Animal Care and Use Committee in accordance 
with the German Animal Protection Law. Unless stated otherwise, the mice were housed in 
groups of 3-5 in standard plastic cages for behavioral testing, with food and water ad 
libitum. The temperature in the colony room was maintained at 20-22 °C, with a 12 h light-
dark cycle (lights on at 8:00 AM). All behavioral experiments were conducted by a blinded 
investigator unaware of the genotype during the light phase of the day (between 8:30 AM 
and 6:00 PM). Basic behavioral functions were assessed in two large consecutive cohorts of 
male and female mice in the following order: elevated plus maze, open field, rotarod, pre-
pulse inhibition of the startle response (PPI), hearing, olfaction, hot plate. Only males were 
subjected to the working and reference memory version of the hole board task. The age of 
mice at the beginning of testing was 11 weeks. Inter-test intervals varied depending on the 
degree of the test invasiveness of the respective test but were at least 1 day. During the time 
of behavioral testing, the weights of the mice were measured approximately every other 
week. 
 
Elevated Plus Maze Test 
This test measures anxiety-related behavior in a novel environment. The cross-shaped 
apparatus made of grey Perspex consisted of two open (l: 30 x h: 15 x w: 5 cm) and two 
walled arms (30 x 15 x 5 cm), which were elevated from the floor to a height of 40 cm. 
Illumination intensity was set to 135 lux. It is assumed that a very anxious mouse would 
spend significantly more time in the walled arms as compared to a less anxious mouse and 
would also show an increased avoidance of the fear-inducing open arms as compared to a 
less anxious mouse. The mice were placed on the maze facing an open arm and were 
observed for 5 min. During this time, the duration spent (s) in the open and the closed arms 
were measured using the automated tracking software Viewer 2. After each trial, the 





Open Field Test 
In order to examine exploratory activity and anxiety-related behavior in a novel 
environment, the animals were exposed to a large circular open field (diameter 120 cm, 
height 25 cm) that was divided into 3 concentric zones. While the activity in the peripheral 
zone is considered to be indicative of exploratory behavior, the activity in the intermediate 
and center zones of the apparatus are thought to reflect anxiety-like behavior. Given that 
rodents tend to avoid open unsheltered spaces they generally spend significantly more time 
in the periphery as compared to the intermediate and center zones. The open field was 
made of grey Perspex. Individual animals were placed in the center of the open field and 
were allowed to explore it for 7 min. The following parameters were measured using the 
same automated tracking system as described for the elevated plus-maze test: a) distance 
traveled and b) the time spent in the central, intermediate, and peripheral zones of the open 
field. After each trial, the apparatus was cleaned with water followed by 70 % ethanol. 
Rotarod  
The rotarod comprised a rotating drum which was accelerated from 4 to 40 rpm over the 
course of 5 min. Individual mice were placed on the drum and once they were balanced, the 
drum was accelerated. The time in seconds at which the respective animal fell from the 
drum was recorded using a trip switch. Each animal went through two consecutive trials at 
one trial per day.  
Pre-pulse Inhibition  
Individual mice were placed in small metal cages (8.2 x 4.0 x 4.0 cm) to restrict movements 
and ambulation. The cages were attached to a sensor that recorded vertical movements of 
the floor. The cages were placed in four sound-attenuated cabinets. Startle reflexes were 
evoked by acoustic stimuli delivered by a loudspeaker that was suspended above the cage 
and connected to an acoustic generator. The startle reaction initiated a movement of the 
platform, which generated a transient force. A recording device registered the force exerted 
onto the platform for 260 ms. Recording was started simultaneously with the onset of the 
acoustic stimulus. All acoustic stimuli used had a frequency of 10 kHz but differed in terms of 
loudness (dB). An experimental session consisted of a 2 min habituation period to the 
continuous white noise with an intensity of 65 dB. This background noise was present 





recording for 1 min. After baseline recording, six pulse-alone trials using startle stimuli of 
120 dB intensity and 40 ms duration were applied to decrease the influence of within-
session habituation. This data was not included in the 120 dB/40 ms analysis of the pre-pulse 
inhibition. For tests of pre-pulse inhibition, the startle pulse was applied either alone or after 
the application of a pre-pulse stimulus of 70 dB, 75 dB, or 80 dB intensity and with a 
duration of 20 ms. An inter-puls-interval of 100 ms with background white noise was used 
between each pre-pulse and pulse stimulus. The trials were presented in a pseudorandom 
order with an interval ranging from 8 to 22 s. The amplitude of the startle response 
(expressed in arbitrary units) was defined as a difference between the maximum force 
detected during the recording window and the force measured immediately before the 
stimulus onset. Amplitudes were averaged for each individual animal, separately for both 
types of trials (i.e. stimulus alone or stimulus preceded by a pre-pulse). Pre-pulse inhibition 
was calculated as percentage of the startle response using the following formula: % pre-
pulse inhibition = 100 - [(startle amplitude after pre-pulse) / (startle amplitude after pulse 
only) x 100]. 
Hearing 
Hearing was measured in the same apparatus as pre-pulse inhibition by the determination of 
the threshold intensity that was able to evoke a maximal acoustic startle response. The 
mouse was placed in the metal cage and the tones were randomly presented. The intensity 
of the tones ranged from 68 to 120 dB. In healthy mice, the startle response increases with 
increased stimulus intensity. The startle amplitudes were measured and plotted. 
Buried food finding test 
Starting 6 days before testing, the mice were habituated to clear cages (29.5 x 18.5 x 13 cm) 
for 30 min, with 3 trials per day. Starting four days before testing, the mice received a piece 
of chocolate cookie (1.6 g) during each habituation trial. Additionally, the mice received 3-5 
cookies in their home cage overnight. Once the mice regularly consumed the cookies during 
the habituation trials, testing was performed on the next day. Starting 24-48 h before 
testing, the mice were deprived of food but with water available ad libitum. For testing, 
individual mice were placed into clear cages filled with bedding up to a height of 1.5 cm, in 
which a piece of chocolate cookie was hidden at a distance of approximately 3 cm from the 





needed to find the food, i.e. the time from the moment the mouse was placed into the cage 
to the time it located the cookie and initiated digging, was recorded. As soon as the cookie 
was detected, the mouse was removed from the cage. Fresh bedding was used for each trial. 
Hot plate 
The hot plate test evaluates pain/heat perception in mice. In this test heat was used as the 
noxious stimulus and the latency of the animal's response to the stimulus was recorded as 
the dependent variable. The hot plate apparatus had a temperature of 55 ± 0.1 °C. The 
mouse was placed into the apparatus and the time until the mouse started licking its paws 
was measured (time cut-off: 40 s). Immediately after showing the licking response, the 
animal was removed from the plate and placed back into its home cage.  
Reference and working memory version of the hole board test 
The hole board task evaluates both working and reference memory in mice. It consists of an 
open field with 16 holes drilled into the floor. Mice readily show nose pokes into the holes 
while exploring the hole board. Nose pokes are registered by infrared light beams. The 
number of nose pokes to each of the 16 holes is recorded and used to calculate working and 
reference memory errors.  
The test is comprised of different phases including habituation, acquisition, long-term 
retention, and reversal learning. The basic procedure was followed with minor modifications 
(Kuc et al., 2006). During habituation, the mice were trained to investigate each of the 16 
holes. Every hole was baited with 6 μl 6 % sucrose solution. A trial was terminated after the 
animal had visited all 16 holes or at the latest after 15 min. During the habituation phase 
each mouse was tested once per day for 6 days.  
During the acquisition stage, only 4 out of the 16 holes were baited with 6 μl 6 % sucrose 
solution. The combination of baited holes remained the same throughout the acquisition 
phase. Over the course of 6 days, each mouse received 2 trials with an inter-trial interval of 
2.5 h. A trial was terminated after the animal had visited all the 4 baited holes or after 5 min 
(cut off). From the number of visits to each of the 16 holes, a number of parameters were 
determined separately for the first and second trial of a given day to evaluate spatial 
learning performance. Two parameters were calculated from the raw data: first reference 
memory errors, i.e. each visit to a non-baited hole, and working memory errors, i.e. each re-





long-term memory with 2 trials per day over 4 days. The procedure was identical to the one 
described for the acquisition phase.  
The day after the last long-term retention trial, the animals were subjected to a novel 
combination of baited holes in order to measure reversal learning, which is thought to 
measure prefrontal cortex function. The animals were tested with 2 trials per day over 2 
days and the procedure was identical to the one described for the acquisition phase.  
2.7.8 Electrophysiology – gamma oscillation 
Gamma oscillation was measured in collaboration with Dr. Sonja Wojcik by Christoph 
Bredack.  
Preparation of acute slices 
Male mice 41-46 days of age were anesthetized by isoflurane and decapitated. The brain 
was quickly dissected and put into ice-cold sucrose based slicing solution, which was bubbled 
with carbogen gas. Brains were trimmed and serial horizontal sections of 400 µm were cut 
using a vibratome. During the sectioning the tissue was immersed in ice-cold sucrose based 
solution and oxygenated with carbogen. The sections were transferred to a custom-made 
interface holding chamber until recording. The solution was pre-warmed to 30 °C, 
continuously bubbled with carbogen gas and kept under constant stirring. 
Gamma oscillations in interface conditions 
After slicing, the sections were kept in a custom-made interface holding chamber. The ACSF 
was kept under constant stirring, saturated with carbogen gas. Network activity was 
recorded in 400 µm thick hippocampal slices cut in horizontal orientation in an interface 
recording chamber at 33 °C. Slices were kept on a nylon mesh at the interface of a stream of 
extracellular recording solution and a stream of warm, moist carbogen gas. Extracellular 
recording electrodes with a resistance of around 2 MΩ were filled with extracellular solution 
and placed in the pyramidal cell layer of the CA3b region in the hippocampus. Extracellular 
field potentials were recorded with a MultiClamp 700B amplifier and a Digidata 1440 A, 
filtered at 3 kHz and a gain of 100 with a Bessel filter. Gamma oscillations were induced by 
bath application of 100 nM kainate. Stable and long lasting oscillatory activity could be 
recorded 5-7 min after the start of kainate application. Baseline field-potentials were 
recorded for 20 min and gamma-oscillation field potentials for 2 times 20 min. Data were 





calculated for twelve-minute epochs (last 12 min of each recording) of recorded field 
activity. Baseline power spectra were subtracted from kainate traces and the frequency and 
the power of the maximum peak was determined.  
2.7.9 Electrophysiology - Long Term Potentiation (LTP) 
LTP was measured in male mice (39-51 days of age) in collaboration with Prof. Michael 
Müller by Oliwia Jank. Field excitatory postsynaptic potentials (fEPSPs) were elicited by 
0.1 ms unipolar stimuli (Grass S88 stimulator with PSIU6 stimulus isolation units) delivered 
via steel micro wire electrodes (50 µm diameter) that were placed on the surface of the 
stratum radiatum of the hippocampus CA1 area. Orthodromic responses were elicited by 
stimulation of Schaffer collaterals and recorded in the apical dendrites of stratum radiatum 
of the CA1 region with a locally constructed extracellular DC-potential amplifier via a glass 
electrode filled with ACSF solution. An input-output curve was generated to determine the 
stimulus strength needed to elicit a half-maximal field excitatory post-synaptic potential 
(fEPSP). Baseline fEPSP was determined using the half-maximal stimulus intensity (current), 
and a low stimulation frequency (0.71 Hz) (measured every 15 s and 4 times averaged for 
1 min). Long term potentiation (LTP) was induced by giving 3 tetanic stimuli of 100Hz for 1 s 
every 5 min. LTP was calculated by averaging the normalized fEPSP amplitude collected for 
60 min after the last tetanic stimulus. All electrophysiological data were sampled using an 
Axon Instruments Digitizer 1322A and pClamp 9.2 software.  
2.7.10 Statistics 
The EPOR mRNA and the cEPOR protein level, hematocrit, and the body weight data were 
statistically analyzed by unpaired two-tailed student t-test. Open field (distance), buried 
food test, and hot plate were analyzed by 1-way ANOVA. Elevated plus maze, open field 
(time in zones), prepulse inhibition, and startle response were analyzed by 2-way ANOVA.  
Rotarod, hole board, gamma oscillation, and STP and LTP data were analyzed by 1-way 
ANOVA for repeated measures. All data were expressed as mean±SEM. Results were 
considered significant if p-values smaller than 0.05 were obtained. All data were plotted and 














Product   Supplier     Product number 
Acrylamide 30 %  Merck KGaA, Darmstadt (Germany)   100639 
Agarose (UltraPure)  Life Technologies GmbH, Darmstadt (Germany)  16500500 
Albumin standard (2 mg/ml) Thermo Scientific, Rockford (USA)   23210 
Ammonium persulfate (APS) Sigma-Aldrich, Taufkirchen (Germany)   A-3678 
Amylalcohol    Merck KGaA, Darmstadt (Germany)    100999 
Aprotinin   Roche Diagnostics GmbH, Mannheim (Germany) 10236624001 
Arabinose   Sigma-Aldrich, Taufkirchen (Germany)   A3256 
Aqua-Poly/Mount  Polyscience, Philadelphia (USA)    18606 
Bacto-Agar   BD, Heidelberg (Germany)    211705 
Boric acid    Merck KGaA, Darmstadt (Germany)   100165 
Bromophenol blue  Sigma-Aldrich, Taufkirchen (Germany)   B5525 
BSA 10mg/ml (100x)  New England Biolabs (NEB), Hitchin (UK)   B9001S 
Chloroform    Merck KGaA, Darmstadt (Germany)   102445 
Citric acid monohydrate Merck KGaA, Darmstadt (Germany)   100244 
CL-4B Sepharose  Sigma-Aldrich, Taufkirchen (Germany)   CL4B200 
CuSO4    Merck KGaA, Darmstadt (Germany)   102790 
EDTA    Sigma-Aldrich, Taufkirchen (Germany)   E5134 
Ethidium bromide 1 % (EtBr) Merck KGaA, Darmstadt (Germany)   1116080030 
Ethylene glycol   Sigma-Aldrich, Taufkirchen (Germany)   293237 
Folin-Ciocalteu reagent  Merck KGaA, Darmstadt (Germany)    109001 
Glycin    Sigma-Aldrich, Taufkirchen (Germany)   33226 
Formaldehyde   Merck KGaA, Darmstadt (Germany)   104003 
Glacial acetic acid   Merck KGaA, Darmstadt (Germany)   100063 
Glycerol 85 %   Merck KGaA, Darmstadt (Germany)   104094 
HCl 37 %   Merck KGaA, Darmstadt (Germany)   100317 
H2O2    Merck KGaA, Darmstadt (Germany)   107210 
Isopropanol   Merck KGaA, Darmstadt (Germany)   109634 
Isoflurane   Actavis Deutschland GmbH & Co. K, München (Germany) 
K-Na-tartrate    Merck KGaA, Darmstadt (Germany)   108087 
LB medium   Sigma-Aldrich, Taufkirchen (Germany)   L3522 
Leupeptin   Roche Diagnostics GmbH, Mannheim (Germany) 11017101001  
ß-Mercaptoethanol  Sigma-Aldrich, Taufkirchen (Germany)    M-3148 
Na2CO3    Merck KGaA, Darmstadt (Germany)   106392 
NaOH    Merck KGaA, Darmstadt (Germany)   106498 
Normal horse serum  Jackson ImmunoResearch Laboratories, Inc. (USA) 008-000-121 
Nonfat dried milkpowder AppliChem, Darmstadt (Germany)   A0830 
Phosphosafe buffer  Merck KGaA, Darmstadt (Germany)   71296-3 
Ponceau-S solution  SERVA Electrophoresis GmbH, Heidelberg (Germany) 33427  
Power SYBR Green  Life Technologies GmbH, Darmstadt (Germany)  4367659 
Pyronin Y   Sigma-Aldrich, Taufkirchen (Germany)   P-7017 
Ringer solution   B.Braun Melsungen AG, Melsungen (Germany)  64341242 
SDS (sodium dodecyl sulfate) Sigma-Aldrich, Taufkirchen (Germany)    L-4509 
Sodium citrate dihydrate Merck KGaA, Darmstadt (Germany) 112005 (new no. 106448) 
Sucrose   Merck KGaA, Darmstadt (Germany)   107651 
TEMED    SERVA Electrophoresis GmbH, Heidelberg (Germany) 35925 





Trizma base   Sigma-Aldrich, Taufkirchen (Germany)   T1503 
Tissue-Tek   VWR International GmbH, Darmstadt (Germany)  25608-930 
TritonX-100   Sigma-Aldrich, Taufkirchen (Germany)   T8787 
Trizma base   Sigma-Aldrich, Taufkirchen (Germany)   T1503 
Tween20    Sigma-Aldrich, Taufkirchen (Germany)   P7949 
2.8.2 Consumables 
Product   Supplier     Product number 
Chromatography paper  GE Healthcare Life Sciences, Buckinghamshire (UK) 303091  
Cryotubes   VWR International GmbH, Darmstadt (Germany)  479-3221 
Electroporation cuvettes Carl Roth GmbH + CO KG, Karlsruhe (Germany)  PP38.1 
Hematocrit sealing compound BRAND GmbH and CO KG, Werheim (Germany)  749510 
Microvette 500 EDTA  SARSTEDT AG & Co., Nümbrecht (Germany)   20.1341 
Micro-hematocrit capillaries BRAND GmbH and CO KG, Werheim (Germany)  749311 
Microwell plate 96  Thermo Fisher Scientific, Roskilde (Denmark)  269620 
Multiwell plate 384  Roche Diagnostics, Mannheim (Germany)  04729749001 
Nitrocellulose membrane GE Healthcare Life Sciences, Buckinghamshire (UK) 10401396 
PAP pen    Zytomed Systems, Berlin (Germany)   LP 0002 
SuperFrost ultra plus slides MenzelGmbH, Braunschweig (Germany)  J1800AMN 
2.8.3 Equipment 
Product     Supplier 
Axon Digidata 1440 A    Molecular Devices, Sunnyvale (USA) 
Axon MultiClamp 700B amplifier  Molecular Devices, Sunnyvale (USA)  
Cryostat CM 1900    Leica, Wetzlar (Germany) 
Vibratome VT1200S     Leica, Wetzlar (Germany) 
EpMotion robot 5075    Eppendorf AG, Hamburg (Germany) 
Grass S88 stimulator    Grass Instruments, Warwick (USA) 
(with PSIU6 stimulus isolation units) 
Interface recording chamber    Harvard apparatus, Freiburg (Germany) 
(BSC-BU Base Unit with BSC-HT Haas Top)  
Light Cycler 480    Roche Diagnostics GmbH, Mannheim (Germany) 
Leica DMI 6000B    Leica Microsystems CMS GmbH, Wetzlar (Germany) 
Microplate reader Revelation   Dynex Technologies, Frankfurt (Germany) 
Mini-peristaltic pump    Harvard Apparatus, Freiburg (Germany) 
Polytron PT1200E    KINEMATICA AG, Luzern (Switzerland)  
PPI cages     TSE Systems GmbH, Bad Homburg (Germany) 
Rotarod     Med associates Inc., St. Albans (UK) 
Steel micro wire electrodes 50 µm diameter A-M Systems, Sequim (USA) 
T3 Thermocycler    Biometra GmbH, Göttingen (Germany) 
Thermomixer Compact    Eppendorf AG, Hamburg (Germany)   
UNO Thermocylcer    Biometra, Göttingen (Germany) 
Vibratome VT1200S     Leica, Wetzlar (Germany) 
Water purification system arium 611  Sartorius, Göttingen (Germany) 
 
Centrifuges 
Megafuge 16R     Thermo Fisher Scientific, Bonn (Germany)  
Megafuge 3.0     Thermo Fisher Scientific, Bonn (Germany) 
Megafuge 2.0      Thermo Fisher Scientific, Bonn (Germany) 
Centrifuge 5416    Eppendorf AG, Hamburg (Germany)   





Mini Spin Plus     Eppendorf AG, Hamburg (Germany)   
Centrifuge 5415    Eppendorf AG, Hamburg (Germany)   
Biofuge Haemo     Thermo Fisher Scientific, Bonn (Germany) 
2.8.4 Software 
Product     Supplier 
Software LAS AF 3    Leica Microsystems CMS GmbH, Wetzlar (Germany) 
Fiji      Free open source software (http://fiji.sc/Fiji) 
SPSS      IBM Deutschland GmbH, Ehningen (Germany) 
GraphPad Prism 5    GraphPad Software Inc., La Jolla (USA) 
Viewer 2      BIOBSERVE GmbH, St. Augustin (Germany) 
AxographX      Axon Instruments Inc., Foster City (USA)  
Axon Instruments Digitizer 1322A  Molecular Devices, Sunnyvale (USA)  
(and pClamp 9.2)  
2.8.5 Enzymes  
Product   Supplier      Product number 
Pfu polymerase   Agilent Technologies GmbH, Böblingen (Germany) 600153  
T4 DNA ligase 1 U/µl  Life Technologies GmbH, Darmstadt (Germany)  15224-025 
rAPid alkaline phosphatase Roche Diagnostics GmbH, Mannheim (Germany) 04898141001 
RED Taq DNA polymerase Sigma-Aldrich, Taufkirchen (Germany)   D4309 
BstBI (20 U/µl)   New England Biolabs (NEB), Hitchin (UK)  R0519 
EcoRV    New England Biolabs (NEB), Hitchin (UK)  R0195  
NotI (10 U/µl)   New England Biolabs (NEB), Hitchin (UK)  R0189 
SalI    New England Biolabs (NEB), Hitchin (UK)  R0138  
XhoI    New England Biolabs (NEB), Hitchin (UK)  R0146  
SacI    New England Biolabs (NEB), Hitchin (UK)  R0156 
PacI (10 U/µl)   New England Biolabs (NEB), Hitchin (UK)  R0547 
PmeI (10 U/µl)   New England Biolabs (NEB), Hitchin (UK)  R0560 
EcoRI (20 U/µl)   New England Biolabs (NEB), Hitchin (UK)  R0101 
NheI (20 U/µl)   New England Biolabs (NEB), Hitchin (UK)  R0131  
RNase A   Roche Diagnostics GmbH, Mannheim (Germany) 10109169001 
SuperScript III    Life Technologies GmbH, Darmstadt (Germany)  18080-044 
2.8.6 Kits 
Product   Supplier     Product number 
ABC kit    Vector Laboratories, Burlingame (USA)   PK-4000 
miRNeasy Mini Kit  Qiagen, Hilden (Germany)    217004  
MSB Spin PCRapace  STRATEC Molecular GmbH, Berlin (Germany)   1020220200 
Nucleobond BAC 100  MACHERY-NAGEL GmbH & Co. KG, Düren (Germany) 740579 
NucleoSpin Tissue Kit  MACHERY-NAGEL GmbH & Co. KG, Düren (Germany) 740952 
PureLink Quick   Life Technologies GmbH, Darmstadt (Germany)  K2100-10  
Plasmid Miniprep Kit  Life Technologies GmbH, Darmstadt (Germany)  K2100-05  
Plasmid Midiprep Kit   Life Technologies GmbH, Darmstadt (Germany)  K2100-06 
Plasmid Maxiprep Kit   Qiagen, Hilden (Germany)     12362 
QIAprep Spin    Qiagen, Hilden (Germany)    27106 






Product   Supplier     Product number 
1 kb DNA ladder  Life Technologies GmbH, Darmstadt (Germany)  15615-016 
100 bp Plus DNA ladder Thermo Fisher Scientific, Bonn (Germany)  SM0321 
Midrange I PFG marker  New England Biolabs (NEB), Hitchin (UK)  N3551S 
Prestained protein ladder Thermo Fisher Scientific, Roskilde (Denmark)  26119 
 
2.8.8 Buffers and solutions 
10x TBE (10 l) 
1.08 kg Tris base 
550 g Boric acid 
400 ml 0.5 M EDTA 
 
50x TAE (1 l) 
242 g Tris base 
57.1 ml glacial acetic acid 
100 ml 0.5 M EDTA pH=8.0 
Filled up to 900 ml with ddH2O, pH adjusted to 8.0 with HCl, then filled up to 1 l with ddH2O. 
 
5x Loading buffer for agarose gels/STOP-MIX (10 ml): 
5 ml Glycerol (50 %) 
20 µl 0,5 M EDTA pH 8.0 (1 mM) 
15 mg Bromophenol blue (0.15 %) 
5 ml ddH2O 
 
STET buffer (100 ml): 
5 ml 1M TrisHCl pH=8.0 (50 mM) 
10 ml 0.5M EDTA (50 mM) 
5 g TritonX-100 (5 %) 
5 g Saccharose (8 %) 
TritonX-100 added after sterile filtration, stored at 4 °C. 
 
Injection buffer (500 ml): 
5 ml 1 M Tris pH=7.5 (10 mM) 
100 µl 0.5 M EDTA pH=8.0 (0.1 mM) 
10 ml 5 M NaCl (100 mM) 
484.9 ml endotoxinfree water 
Filtered sterile through 0.2 µm pore filter. 
 
Avertin (100 ml) 
1 g Tribromoethanol  
71.49 ml Pre-warmed H2O (40 °C)  
0.81 ml Amylalcohol  
Mixed in a small glass bottle, stirred for 10 min, sterile filtered, stored at 4 °C for a maximum of one 
week. 
 
4 % FA (100 ml) 
10.81 ml 37 % Formaldehyde solution 






20x PBS (2 l) 
8 g NaCl 
320 g KCl 
57,6 g Na₂HPO₄ 
9,6 g KH₂PO₄ 
Filled up to 2 l with ddH₂O, adjusted to pH=7.4. 
 
Ethylene glycol cryoprotectant solution (2 l) 
498 ml Glycerol (85 %) 
588 ml Ethylene glycol 
912 ml PBS (1x) 
 
Citrate buffer (10mM) 
Stock solution A: 21.01 g Citric acid monohydrate in 1 l ddH₂O 
Stock solution B: 29.42 g Sodium citrate dehydrate in 1 l ddH₂O 
10x Ready-to-use-solution: 3 ml of stock A and 17 ml of stock B, pH adjusted to 6. 
 
4x Laemmli buffer (10 ml)  
2.5 ml 1M Tris HCl (pH=8.3)  
0.8 g SDS     
4 ml Glycerin    
2 ml ß-Mercaptoethanol   
4 mg Pyronin Y    
1.5 ml ddH₂O  
 
0.1 M NaOH 
2 g NaOH solved in 500 ml ddH₂O 
 
2 % Na2CO3  
10 g Na2CO3 solved in 500 ml 0.1 M NaOH 
 
2 % K-Na-tartrat 
10 g K-Na-tartrat solved in 500 ml ddH₂O 
 
1 % CuSO4 
5 g CuSO4 x 5H₂O solved in 500 ml ddH₂O 
 
Fresh copper solution (20.4 ml) 
20 ml 2 % Na2CO3 (100 parts) 
200 µl 2 % K-Na-tartrat (1 part) 
200 µl 1 % CuSO4 (1 part) 
 
10 % SDS stock solution 
50 g SDS 
Filled up to 500 ml with ddH₂O and filtered sterile. 
 
Gel lower buffer 
182 g Tris Base 
40 ml 10 % SDS (0.4 %) 









Gel upper buffer 
60.5 g Tris Base 
40 ml 10 %SDS (0.4 %) 
Tris base dissolved in 900 ml ddH₂O, pH adjusted to 6.8 with HCl, SDS added, filled up to 1 l with 
ddH₂O. 
 
5x Running buffer  
15 g Tris Base 
93.89 g Glycine 
5 g SDS 
Filled up to 1 l with ddH₂O. 
 
5x Transfer buffer 
12.13 g Tris Base 
57.68 g Glycine 
Filled up to 1 l with ddH₂O. 
 
20x TBS (2 l) 
242 g Tris base 
350 g NaCl 
Filled up to 2 l with ddH₂O. 
 
1x TBST (5 l) 
250 ml 20x TBS 
2.5 ml Tween20 
Filled up to 5 l with ddH₂O and mixed for 5 min. 
 
Stripping buffer (1 l) 
125 ml 0.5 M Tris HCl (pH=6.8) 
20 g SDS 
7ml ß-Mercaptoethanol 
Filled up to 1 l with ddH₂O and stored at 4 °C. 
 
5x Stock slicing solution  
1150 mM Sucrose 
130 mM NaHCO3 
10 mM KCl 
5 mM KH2OP4 
5 mM MgCl2 x 6H2O 
50 mM Glucose x H2O 
Sterilized by filtration through a 0.22 µm filter and stored at 4 °C. CaCl2 was added to the 1x slice 
solution for 0.5 mM final concentration from a 1 M stock. 
 
Kainate solution 
25 mM in H2O 










10x Stock recording and slice storing solution (ACSF) 
1200 mM NaCl 
260 mM NaHCO3 
10 mM KH2PO4 
20 mM KCl 
20 mM MgCl2 x 6H2O 
100 mM Glucose x H2O 
Sterilized by filtration through a 0.22 µm filter and stored at 4 °C. CaCl2 was added to the 1x solution 












5063 (IL-2) 5'-CTAGGCCACAGAATTGAAAGATCT-3' 
5064 (IL-2) 5'-GTAGGTGGAAATTCTAGCATCATCC-3' 
2521 (Venus) 5'-CATGGTCCTGCTGGAGTTCGTG-3' 
24016 (Venus) 5'-GTCAAGGCACTATACATCAAA-3' 
25763 (polyA) 5'-TGGATCGATCCCGCCATGGTAT-3' 
25764 (polyA) 5'-GGAGCAGGGTGGCTTAATTAAGAAGT-3' 
26857 (5' UTR Viaat) 5'-CTGGCCGTCGACATTTAGGTG-3' 
26858 (5' UTR Viaat) 5'-ATGCTGGGATGTGGGAGGTTCTT -3' 
26859 (pBACe3.6) 5'-TGTCGGGTGCGGAGAAAGAGGTAA-3' 
26860 (pBACe3.6) 5'-TGGCAGGGCGGGGCGTAAT-3' 
cDNA  
4542 (N9) 5'-NNNNNNNNN-3' 
9578 oligo(dT)-Mix  5'-TTTTTTTTTTTTTTTTTTTTTTTVN -3' 
qPCR  
11329 (EPOR) 5'-CCTCATCTCGTTGTTGCTGA-3' 
11330 (EPOR) 5'-CAGGCCAGATCTTCTGCTG-3' 
6038 (GAPDH) 5'-GTGCAGCGAACTTTATTGATGGTATTCAAGAG -3' 




Mouse parvalbumin  Sigma-Aldrich, Taufkirchen (Germany)   P3088 
Rabbit HA   Cell Signaling Technology Inc., Danvers (USA)  #3724 
Mouse HA   Covance Inc., Princeton (USA)    MMS-101P 
Rat HA    Roche Diagnostics GmbH, Mannheim (Germany)  11867423001 
Rabbit HA   Abcam plc, Cambridge (UK)    ab9110  
Rabbit GFP   Synaptic Systems GmbH, Göttingen (Germany)   132002 






Biotinylated anti-rabbit IgG Vector Laboratories, Burlingame (USA)   BA-1000 
Biotinylated anti-mouse IgG Vector Laboratories, Burlingame (USA)   BA-2001 
Goat anti-mouse-AF488 Life Technologies GmbH, Darmstadt (Germany)  A11001 
Donkey anti-rabbit-AF488 Life Technologies GmbH, Darmstadt (Germany)  A-21206 
Streptavidin-AF488  Life Technologies GmbH, Darmstadt (Germany)  S-32354 
Streptavidin-AF633  Life Technologies GmbH, Darmstadt (Germany)  S-21375 
Goat anti-mouse-HRP  Sigma-Aldrich, Taufkirchen (Germany)   A-3682 
Goat anti-rat-HRP  Sigma-Aldrich, Taufkirchen (Germany)   A-9037 
 
Dyes 





3 Results  
The results section is divided into the following parts:  
Part I  - Cloning of the Viaat-HA-cEPOR construct  
Part II  - Analysis of the transgenic Viaat-HA-cEPOR mouse 
Results Part I 
3.1 Cloning of Viaat-HA-cEPOR (± IRES-Venus) 
The basis of the Viaat-HA-cEPOR construct was the alpha-CaMKII-HA-cEPOR vector, which 
was used for the generation of the alpha-CaMKII-HA-cEPOR mice, published in 2011 (Sargin 
et al., 2011). The HA-cEPOR construct was cut out and placed under control of the Viaat 
promoter, using the mouse bacterial artificial chromosome (BAC) RP23-392P11. RP23-
392P11 contains the SLC32A1 gene (solute carrier family 32 member 1) coding for the 
vesicular inhibitory amino acid transporter (Viaat), also known as vesicular GABA transporter 
(VGAT). Importantly, the BAC includes the upstream region of 125 kb and the downstream 
region of 68 kb and therefore most likely contains all regulatory sequences necessary for 
gene expression. The detection of HA-cEPOR expression was problematic in the alpha-
CaMKII-HA-cEPOR mice and the staining against the HA-tag was very weak. Therefore, this 
study aimed to include an additional construct with a fluorescent marker. The internal 
ribosomal entry site (IRES)-Venus was chosen as alternative for the detection of cEPOR. This 
construct was named Viaat-HA-cEPOR-IRES-Venus. The cloning of both constructs, Viaat-HA-
cEPOR and Viaat-HA-cEPOR-IRES-Venus, is explained in detail on the following pages.  
3.1.1 Step 1 - Validation of restriction cutting sites of alpha-CaMKII-HA-cEPOR 
The alpha-CaMKII-HA-cEPOR vector was used as basis for cloning the Viaat-HA-cEPOR and 
Viaat-HA-cEPOR-IRES-Venus construct. In the first step, several restriction cutting sites, 
which were used in the following cloning procedures, were tested. The results of the 
restriction digests with KpnI, NotI, SalI, EcoRI, SpeI, NruI and SacI are presented in Figure 
17A. The locations of the respective restriction sites are illustrated in Figure 17B, and the 
predicted band sizes for each restriction digest are given in Figure 17C. The alpha-CaMKII-





such as SalI and NruI, produce a 13.953 kb linearized plasmid, which appears as a single band 
on the gel. Circular plasmids would show more than one band because of supercoiled 
structures. Thus, the cutting sites for SalI and NruI were validated. Restriction enzymes with 
more than one cutting site produce fragments with specific sizes. Comparing the predicted 
sizes with the digestion results, the cutting sites for EcoRI, SpeI and SacI could be confirmed. 
But there was a discrepancy between the actual and the predicted sizes for KpnI and NotI 
(Figure 17C, highlighted in red). Based on the fragment sizes obtained, the conclusion was 
that some cutting sites, which were expected from the available plasmid sequence, do not 
exist. These were 2 cutting sites for KpnI and 1 cutting site for NotI, which should have been 
located in the pBS II SK (+) region (Figure 17B encircled in red). For the following cloning 
steps, neither the restriction sites nor the sequence of the source plasmid pBS II SK(+) were 
important. Therefore, the cloning was continued and the experimentally determined 
product sizes were used for further calculations. 
 
Figure 17: Cloning Step 1 - Validation of the restriction sites of alpha-CaMKII-HA-cEPOR. (A) Agarose gel 
visualizing the different fragment sizes of alpha-CaMKII-HA-cEPOR after restriction digest with KpnI, NotI, SalI, 
EcoRI, SpeI, NruI and SacI. The 1 kb ladder was used as size marker. (B) Circular illustration of the plasmid 
alpha-CaMKII-HA-cEPOR with the respective cutting sites for the restriction enzymes KpnI, NotI, SalI EcoRI, 
SpeI, NruI and SacI. The promoter region for alpha-CaMKII, the Hybrid Intron (H), the polyA coding sequence, 
and the ampicillin resistance sequence of pBS II SK(+) are drawn in grey. The HA-cEPOR sequence is highlighted 
in red. Encircled in red are 2 cutting sites for KpnI and 1 cutting site for NotI that were expected based on the 
sequence file but could not be verified experimentally. (C) Table of the restriction enzymes with their cutting 
frequency and fragment sizes for alpha-CaMKII-HA-cEPOR. Labeled in red are fragment sizes which are in 





3.1.2 Step 2 - Insertion of IRES-Venus into alpha-CaMKII-HA-cEPOR 
To obtain an alternative for the detection of cEPOR expression, IRES-Venus was inserted into 
the alpha-CaMKII-HA-cEPOR plasmid as illustrated in Figure 18A. For this purpose, 3 µg of 
alpha-CaMKII-HA-cEPOR were linearized with SalI and the insert IRES-Venus was cut out of 
4 µg pcDNA3-EMCV-IRES-PV-IRES-VENUS with EcoRV and NotI. The vector (13.95 kb) and the 
insert (1.52 kb) were separated on a preparative agarose gel and extracted (Figure 18B, red 
dots). The purified fragments were blunt-ended and the vector was dephosphorylated. 
Before ligation, both fragments were analyzed again on the agarose gel (Figure 18C) and 2 
different ratios of vector to insert (10:4 and 8:6) were ligated. Elektro10 cells were 
transformed with the new construct alpha-CaMKII-HA-cEPOR-IRES-Venus and 12 clones 
were picked for a diagnostic restriction digest with KpnI (Figure 18D and E). Clone #1, #2 and 
#10 of ligation mixture 10:4 (Figure 18D) and clone #8, #9, #10, and #11 of ligation mixture 
8:6 (Figure 18E) showed the correct fragment sizes of 9239, 3614, 2298, and 326 bp (326 bp 
is not visible in the picture). Clone #8 was purified, confirmed by sequencing and used for 
cloning step 3. 
 
Figure 18: Cloning step 2 - Insertion of IRES-Venus into alpha-CaMKII-HA-cEPOR. (A) Illustration of the cloning 
step. (B) Preparative agarose gel showing the isolated restriction fragments of alpha-CaMKII-HA-cEPOR (lane 1, 
red dot) and IRES-Venus (lane 2, red dot). (C) Agarose gel presenting the DNA of vector (lane 1) and insert 
(lane 2) before ligation. (D) Agarose gel visualizing the restriction fragments after KpnI digestion of 12 clones 
(#1-12). Ligation ratio of vector to insert is 10:4. (E) Agarose gel visualizing the restriction fragments after KpnI 
digestion of 12 clones (#1-12). Ligation ratio of vector to insert is 8:6. Framed are clones with correct fragment 





3.1.3 Step 3 - Insertion of ampicillin resistance (AmpR) with FRT sites 
In the following cloning step HA-cEPOR and HA-cEPOR-IRES-Venus were cloned into the 
phCre2myc_nucNP plasmid to obtain an FRT-framed ampicillin resistance gene. The 
resistance gene is needed in cloning step 10 for selecting clones after successful homologous 
recombination. The FRT sites enable removal of the bacterial resistance gene from the BAC 
before linearization and integration into the mouse genome. In this step, 5 µg 
phCre2myc_nucNP were cut with XhoI and 7 µg of alpha-CaMKII-HA-cEPOR±IRES-Venus were 
cut with NotI. The digestion fragments were purified and blunt-ended. Vector and inserts 
were then cut with SacI. The cEPOR gene contains an internal restriction site for SacI; the 
missing 5' fragment was introduced as part of the 5' miniarm in the next step. The fragments 
of the restriction digests were separated on a preparative agarose gel (Figure 19A). The 
vector phCre2myc_nucNP (3.13 kb, lane 1, red dot) and the inserts HA-cEPOR (2.446 kb, lane 
3, red dot) and HA-cEPOR-IRES-Venus (3.970 kb, lane 2, red dot) were isolated, and purified 
and fragment sizes were again confirmed on an agarose gel (Figure 19B). 
 
Figure 19 Cloning step 3 -Insertion of ampicillin resistance (AmpR) with FRT-site. (A) Preparative agarose gel 
of restrictions fragments after digestion. PhCre2myc_nucNP was digested with XhoI and SacI (lane 1), alpha-
CaMKII-HA-cEPOR digested with NotI and SacI (lane 2) and alpha-CaMKII-HA-cEPOR-IRES-Venus digested with 
NotI and SacI (lane 3). Extracted bands are labeled with a red dot. (B) Agarose gel of vector (lane 1) and inserts 
(lane 2, 3) before ligation. (C) Agarose gel of restriction fragments after PacI + SacI digestion of 9 clones (#1-9) 
of HA-cEPOR-IRES-Venus-frtAmpRfrt. (D) Agarose gel visualizing the restriction fragments after PacI, SacI 
digestion of 6 clones (#1-6) of HA-cEPOR- frtAmpRfrt. Framed are clones with correct fragment sizes. (E) Table 
of constructs and product sizes after cutting with the respective restriction enzymes. (F) Illustration of the new 
constructs HA-cEPOR-IRES-Venus-frtAmpRfrt and HA-cEPOR- frtAmpRfrt. On all agarose gels, the 1 kb ladder 





XL1-Blue cells were transformed with the ligated construct. The clones were analyzed with a 
PacI+SacI digestion (Figure 19C, D). Clones with the correct plasmid of HA-cEPOR-IRES-
Venus-frtAmpRfrt (Figure 19C, E, F) should have fragment sizes of 5176 bp and 1921 bp. 
Clones with the correct plasmid of HA-cEPOR-frtAmpRfrt (Figure 19D, E, F) should have 
fragment sizes of 3652 bp and 1921 bp. Clones #5 and #6 showed correct fragment sizes for 
HA-cEPOR-IRES-Venus-frtAmpRfrt (Figure 19C, framed), clone #1 for HA-cEPOR-frtAmpRfrt 
(Figure 19E, framed). All three clones were confirmed by sequencing and clone #6 and #1 
were used for further cloning.  
3.1.4 Step 4 - Creation of 5' and 3' miniarms for recombineering 
The aim was to integrate the Viaat-HA-cEPOR±IRES-Venus construct into the BAC RP23-
392P11 by homologous recombination (cloning step 10). For this purpose, the cEPOR 
construct had to be framed by sequences homologous to the desired integration site. In this 
step, the homologous sequences (called 5' and 3' miniarms) were created by PCR. It has 
been shown that long homology arms of 200-500 bp increase the efficacy of homologous 
recombination to an accuracy of more than 95 % correctly constructed clones (Liu et al., 
2003). Therefore, relatively long miniarms of 400-600 bp were created (see 2.3.1, 2.3.2). 
Since some restriction enzymes do not cut efficiently near the end of fragments, the 
miniarms were cloned afterwards into the pCRII-TOPO vector (Figure 20A, B).  
 
Figure 20: Cloning step 4 - Creation of 5' and 3' miniarms for recombineering. (A,B) Circular illustration of the 
5'miniarm-pCRII-TOPO and 3'miniarm-pCRII-TOPO vector. (C) Agarose gels visualizing the fragment sizes of 
5'miniarm-pCRII-TOPO after diagnostic restriction digest with EcoRI. (D) Agarose gels visualizing the fragment 





The miniarm-TOPO plasmids were transformed into XL-1 Blue cells. The next day, 12 clones 
of each miniarm-TOPO vector were picked for a diagnostic restriction digest with EcoRI. The 
restriction digests were analyzed on an agarose gel. Clone #2, #3, #10, #11 and #12 of the 
5'miniarm-pCRII-TOPO (Figure 20C) and all clones of the 3'miniarm-pCRII-TOPO (Figure 20D) 
were of the correct fragment sizes. 
3.1.5 Step 5 - Insertion of the 5' miniarm 
Now the 5' miniarm, which additionally carries the missing 5' fragment of the HA-cEPOR 
gene, was integrated into the HA-cEPOR-frtAmpRfrt±IRES-Venus construct. For this purpose, 
the 5'miniarm-pCRII-TOPO, HA-cEPOR-frtAmpRfrt and HA-cEPOR-IRES-Venus-frtAmpRfrt 
were cut with SacI. The fragments were separated on a preparative agarose gel (Figure 21A) 
and the fragments of HA-cEPOR-frtAmpRfrt (5.573 kb), HA-cEPOR-IRES-Venus-frtAmpRfrt 
(7.097 kb) and 5'miniarm-pCRII-TOPO (0.813 kb) were purified (Figure 21B). The vectors HA-
cEPOR-frtAmpRfrt and HA-cEPOR-IRES-Venus-frtAmpRfrt were dephosphorylated and ligated 
with the 5' miniarm. The new plasmids HA-cEPOR-frtAmpRfrt-5'miniarm and HA-cEPOR-IRES-
Venus-frtAmpRfrt-5'miniarm, illustrated in (Figure 21C), were transformed into XL-1 Blue 
cells. For a diagnostic restriction digest 12 clones were picked and cut with EcoRI and PacI. 
Clone #6, #8, #11 of HA-cEPOR-frtAmpRfrt-5'miniarm and clone #6, #8, #10, #11 of HA-
cEPOR-IRES-Venus-frtAmpRfrt-5'miniarm showed the predicted fragment sizes (Figure 21D, 
E, F). Clone #6 of HA-cEPOR-frtAmpRfrt-5'miniarm and clone #10 of HA-cEPOR-IRES-Venus-
frtAmpRfrt-5'miniarm were confirmed by sequencing and used for further cloning. 
3.1.6 Step 6 - Insertion of the 3' miniarm and a kanamycin resistance (KanR)  
Cloning step 6 was a 3-way ligation, in which the 3' miniarm and an additional Kanamycin 
resistance gene (KanR) were integrated. For this purpose, the HA-cEPOR-frtAmpRfrt-
5'miniarm and the HA-cEPOR-IRES-Venus-frtAmpRfrt-5'miniarm were cut with EcoRI and 
PacI, the 3'miniarm-pCRII-TOPO was cut with NheI and PacI and the plasmid pEGFP-N, which 
contains the KanR, was cut with EcoRI and NheI. All digests were separated on a preparative 
agarose gel (Figure 22A, B). All four fragments were isolated and controlled on an agarose 
gel before ligation (Figure 22C). XL1-Blue cells were transformed with the new plasmids HA-
cEPOR-frtAmpRfrt-5'3'miniarm-KanR (Figure 22F) and HA-cEPOR-IRES-Venus-frtAmpRfrt-
5'3'miniarm-KanR (Figure 22G). Only a few clones grew on Amp/Kan agar plates and all had 






Figure 21: Cloning Step 5 - Insertion of the 5' miniarm. (A) Preparative agarose gel after SacI digestion; HA-
cEPOR-frtAmpRfrt (lane 1) HA-cEPOR-IRES-Venus-frtAmpRfrt (lane 2) and 5'miniarm-pCRII-TOPO (lane 3). 
Extracted bands are labeled with a red dot. (B) Agarose gel of HA-cEPOR-frtAmpRfrt (lane 1), HA-cEPOR-IRES-
Venus-frtAmpRfrt (lane 2), and 5'miniarm-pCRII-TOPO (lane 3) before ligation. (C) Illustration of the new 
constructs. (D) Agarose gel after EcoRI, PacI digestion of 12 clones (#1-12) of HA-cEPOR-frtAmpRfrt-5'miniarm. 
(E) Agarose gel after EcoRI, PacI digestion of 12 clones (#1-12) of HA-cEPOR-IRES-Venus-frtAmpRfrt-5'miniarm. 
Framed are clones with correct fragment sizes. (F) Table of constructs and fragment sizes after cutting with the 
respective restriction enzymes. In all agarose gels, the 1 kb ladder was used as size marker. 
 
3.1.7 Step 7 - Sequencing of the construct 
HA-cEPOR-frtAmpRfrt-5'3'miniarm-KanR and HA-cEPOR-IRES-Venus-frtAmpRfrt-5'3'miniarm-
KanR were the final plasmid constructs and used for recombineering with the BAC RP23-
392P11, which contains the Viaat gene including the promoter region. Clone #1 of HA-
cEPOR-frtAmpRfrt-5'3'miniarm-KanR and clone #7 of HA-cEPOR-IRES-Venus-frtAmpRfrt-
5'3'miniarm-KanR were amplified (Plasmid Maxi Preparation) and sequenced in order to 







Figure 22: Cloning step 6 - Insertion of the 3' miniarm and a kanamycin resistance (KanR). (A) Preparative 
agarose gel of HA-cEPOR-frtAmpRfrt-5'miniarm after digestion with EcoRI and PacI (lane 1), HA-cEPOR-IRES-
Venus-frtAmpRfrt-5'miniarm after digestion with EcoRI and PacI (lane 2), and 3'miniarm-pCRII-TOPO after 
digestion with NheI and PacI (lane 3). Extracted bands are labeled with a red dot. (B) Preparative agarose gel 
visualizing the restrictions fragment of pEGFP-N1 (KanR) after digestion with EcoRI and NheI. (C) Agarose gel of 
vectors and inserts before ligation, HA-cEPOR-frtAmpRfrt-5'miniarm (lane 1), HA-cEPOR-IRES-Venus-frtAmpRfrt-
5'miniarm (lane 2), 3'miniarm-pCRII-TOPO (lane 3), and pEGFP-N1 (lane 4). (D) Agarose gel of HA-cEPOR-
frtAmpRfrt-5'3'miniarm-KanR after EcoRI, SpeI digestion of clone #1. (E) Agarose gel of EcoRI, SpeI digestion of 
4 clones (#4-7) of HA-cEPOR-IRES-Venus-frtAmpRfrt-5'3'miniarm-KanR. (F, G) Illustration of the new constructs. 
(H) Table with constructs and fragment sizes after cutting with the respective restriction enzymes. In all 















3.1.8 Step 8 - Linearization of the construct 
The last step of the in vitro genetic engineering was the linearization of the two constructs. 
10 µg of HA-cEPOR-frtAmpRfrt-5'3'miniarm-KanR and HA-cEPOR-IRES-Venus-frtAmpRfrt-
5'3'miniarm-KanR were cut with SpeI, EcoRI and BstBI in a volume of 100 µl for 4 h at 37 °C. 
BstBI was used to cut the vector backbone. Without BstBI, both fragments would have been 
almost similar in size and the linearized construct could not have been purified. The 
restriction digestion was separated on a preparative agarose gel (Figure 23A) and purified. 
Before using the linearized construct for recombineering, the fragment sizes and purities 
were confirmed on another agarose gel (Figure 23B). The concentration was 
spectrophotometrically determined. HA-cEPOR-frtAmpRfrt-5'3'miniarm had a concentration 
of 120 ng and HA-cEPOR-IRES-Venus-frtAmpRfrt-5'3'miniarm a concentration of 165 ng. 
Approximately 100-200 ng should be used for recombination. Therefore, 1 µl each was used 
for the recombineering step. 
 
Figure 23: Cloning step 8 - Linearization of HA-cEPOR-(IRES-Venus)-frtAmpRfrt-5'3'miniarm-KanR (A) 
Preparative agarose gel of HA-cEPOR-frtAmpRfrt-5'3'miniarm-KanR after digestion with EcoRI, SpeI and BstBI 
(lane 1), and HA-cEPOR-IRES-Venus-frtAmpRfrt-5'3'miniarm-KanR after digestion with EcoRI, SpeI and BstBI 
(lane2). Extracted bands are labeled with a red dot. (B) Agarose gel presenting the purity and amount of the 
extracted linearized DNA which was later on used for recombineering. (C) Illustration of the linear DNA 
construct HA-cEPOR-frtAmpRfrt-5'3'miniarm used for recombineering. (D) Illustration of the linear DNA 
construct HA-cEPOR-IRES-Venus-frtAmpRfrt-5'3'miniarm used for recombineering. On both agarose gels, the 
1 kb ladder was used as size marker. 
 
3.1.9 Step 9 - Transformation of RP23-392P11 into SW105 
After successful cloning, amplification and linearization of HA-cEPOR-frtAmpRfrt-5'3'miniarm 
and HA-cEPOR-IRES-Venus-frtAmpRfrt-5'3'miniarm, the recombineering had to be set up. 
The BAC RP23-392P11 (Figure 24A) was transformed into the recombinogenic strain SW105. 
For this, the BAC RP23-392P11 was isolated by the BAC mini preparation and visualized on a 
0.7 % TBE agarose gel (Figure 24B). Electrocompetent SW105 cells were transformed with 





#4(1) and #4(2), followed by a diagnostic restriction digest with PacI and PmeI. The 
fragments were separated with PFGE (Figure 24C) and both clones had the same fragment 
sizes as the control, the BAC #4 before transformation. 
 
 
Figure 24: Cloning Step 9 - Transformation of RP23-392P11 into the recombinogenic strain SW105. (A) 
Circular illustration of the BAC RP23-392P11. (B) Agarose gel of the isolated BAC DNA from Clone #3 and #4. 
The 1 kb ladder was used as size marker (C) PFGE showing the fragment sizes of the BAC before and after 
transformation, digested with PacI and PmeI. Midrange I PFG marker was used as size standard. 
 
3.1.10 Step 10 - Recombineering  
Recombinogenic and electrocompetent cells of SW105-RP23-392P11, clone #4(1), were 
transformed with the linearized and purified constructs of HA-cEPOR-(IRES-Venus)-
frtAmpRfrt-5'3'miniarm. To identify clones with successful recombination and integration of 
the EPOR construct into the BAC RP23-392P11 (Figure 25A, B), the isolated BAC DNA was 
digested with PacI and separated by PFGE (Figure 25C, D). Both constructs, Viaat-HA-cEPOR-
frtAmpRfrt and Viaat-HA-cEPOR-IRES-Venus-frtAmpRfrt have an additional restriction site for 
PacI. Thus, by successful recombination, the 29.233kb fragment of the wt-BAC is replaced by 
smaller fragments (Figure 25C and E, highlighted in red). This was the case in clone #1, #4, 
#5, and #6 for Viaat-HA-cEPOR-frtAmpRfrt (1) and clone #2, #4 and #6 for Viaat-HA-cEPOR-
IRES-Venus-frtAmpRfrt (2). These clones were then digested with PmeI (Figure 17D and E). In 
case of successful recombination, the wt fragment size of 40.823 kb should increase to 
44.710 kb (1) or 46.234 kb (2). This was the case for all clones and verified the successful 
recombination. Clone #5 and #6 for Viaat-HA-cEPOR-frtAmpRfrt and clone #2 and #4 for 









Figure 25: Cloning Step 10 - Recombineering. (A,B) Circular illustration of Viaat-HA-cEPOR-frtAmpRfrt and 
Viaat-HA-cEPOR-IRES-Venus-frtAmpRfrt. (C) PFGE visualizing the restriction fragments of 6 clones (#1-6) of 
Viaat-HA-cEPOR-frtAmpRfrt (1) and Viaat-HA-cEPOR-IRES-Venus-frtAmpRfrt (2) after digestion with PacI. The 
BAC RP23-392P11 (C) serves as a control to compare the new fragment sizes. Fragment sizes that change 
through recombineering are marked with a red arrowhead. (D) PFGE of the restrictions fragments of 6 clones 
(#1-6) of Viaat-HA-cEPOR-frtAmpRfrt (1) and Viaat-HA-cEPOR-IRES-Venus-frtAmpRfrt (2) after digestion with 
PmeI. The BAC RP23-392P11 (C) serves as a control to compare the new fragment sizes. (E) Table presenting 
construct and fragment sizes after cutting with the respective restriction enzymes. Fragment sizes, which have 












3.1.11 Step 11 - Excision of the AmpR gene  
The last modifying step of the BAC was the excision of the AmpR gene. For this, clone #5 and 
#6 of Viaat-HA-cEPOR-frtAmpRfrt and clone #2 and #4 of Viaat-HA-cEPOR-IRES-Venus-
frtAmpRfrt were amplified and grown in the presence of arabinose to induce the excision. 
The new BACs were digested with PacI and separated by PFGE (Figure 26A). With a 
successful excision, the fragment 17.211 kb is reduced to 16.049 kb in the case of Viaat-HA-
cEPOR, and the fragment 18.735 kb is reduced to 17.573 kb in the case of Viaat-HA-cEPOR-
IRES-Venus (Figure 26A and D, in red). All clones showed the predicted fragment sizes.  
 
Figure 26: Cloning Step 11 - Excision of the AmpR gene. (A) PFGE of the restriction fragments of Viaat-HA-
cEPOR clones #5 (1, 2) and #6 (1, 2) and Viaat-HA-cEPOR-IRES-Venus clones #2 (1, 2) and #4 (1, 2) after 
digestion with PacI. The BAC RP23-392P11 (C) and the clones before excision (#5, #6, #2, #4) serve as controls 
to compare the new fragment sizes. (B) PFGE of the restriction fragments of Viaat-HA-cEPOR clones #5 (1, 2) 
and Viaat-HA-cEPOR-IRES-Venus clones #2 (1, 2) after digestion with PmeI and MluI. The BAC RP23-392P11 (C) 
and the clones before excision (#5, #2) serve as controls to compare the new fragment sizes. (C) PFGE showing 
the restriction fragments of Viaat-HA-cEPOR clones #5 (1, 2) and Viaat-HA-cEPOR-IRES-Venus clones #2 (1, 2) 
after digestion with PvuI and NruI. The BAC RP23-392P11 (C) and the clones before excision (#5, #2) serve as 
controls to compare the new fragment sizes. (D) Table presenting the constructs and their fragment sizes after 
cutting with the respective restriction enzymes. Fragment sizes, which have changed by successful 





The correct configuration of the BAC clones was confirmed by additional diagnostic digests 
before using them for microinjection. The digestions with PacI and MluI (Figure 26B, D, in 
red) gave no clearly visible differences of the fragment sizes before and after excision).  
In contrast, the PvuI digest showed a clear difference in fragment sizes (Figure 26C and D). 
By excision of AmpR the BAC one cutting site for PvuI is lost and the fragment of 14.678 kb 
increases to 17.644 kb for Viaat-HA-cEPOR and the fragment of 14.678 kb increases to 
16.119 kb for Viaat-HA-cEPOR-IRES-Venus (Figure 26C and D, highlighted in red). The last 
digestion was the digestion with NruI (Figure 26C and D), which was to be used in the next 
step to linearize the BAC for microinjection. The digestion also showed correct fragment 
numbers and sizes for clone #5(1) for Viaat-HA-EPOR and for clone #2(1) for Viaat-HA-EPOR-
IRES-Venus. These clones were chosen and prepared for pronuclear injection. 
3.1.12 Step 12 - Linearization and purification of the BAC for pronuclear injection 
The BACs Viaat-HA-EPOR clone #5(1) and Viaat-HA-EPOR-IRES-Venus clone #2(1) were 
amplified, isolated, and digested with NruI. NruI does not only linearize the constructs, but 
also releases the backbone pBACe3.6. The linearized construct was separated and purified 
on a self-made sepharose column. Fractions of approximately 200 µl were collected and 
25 µl of the fractions with the highest DNA amount were separated by PFGE (Figure 27). The 
early fractions 13 - 19 of Viaat-HA-EPOR and fractions 9 - 15 of Viaat-HA-EPOR-IRES-Venus 
contained visible amounts of the backbone (Figure 27A and B, red arrowheads) and were not 
used for microinjection. Fraction 20 of Viaat-HA-EPOR and fraction 16 of Viaat-HA-EPOR-
IRES-Venus showed clean bands of 184.146 kb or 185.670 kb (Figure 27, framed fractions) 
and no visible backbone contamination.  
 
Figure 27: Cloning Step 12 - Linearization and purification of the BAC for pronuclear injection. (A) PFGE 
showing fraction 13-26 of NruI linearized Viaat-HA-EPOR. (B) PFGE showing fraction 8-21 of NruI linearized 
Viaat-HA-EPOR-IRES-Venus. Framed are the fractions chosen for pronuclear injection. Midrange I PFG Marker 





These fractions were spectrophotometically analyzed and they passed the quality 
requirements with concentrations of 5.1 µg/ml and 5.4 µg/ml and OD260/280 ratios of 1.73 
and 1.82. The fractions were diluted to 1 µg/ml and used for pronuclear injection. Step 12 
was repeated three times to deliver fresh DNA for the different injection dates (pictures and 
data not shown). The DNA was injected into fertilized eggs that were re-implanted into the 
oviducts of pseudopregnant females (foster mothers). The offspring was genotyped to 

















Results part II 
3.2 Analysis of Viaat-HA-cEPOR±IRES-Venus mouse lines 
3.2.1 Identification of transgenic offspring by genotyping PCR – F0 generation 
The offspring of all foster mothers were genotyped with the primer pair 25763/25764, which 
binds in the polyA signal sequence of the construct (Figure 28), and a primer pair for IL-2 as 
internal control. The animals positive for the transgene were then genotyped with three 
additional primer pairs. Primer pair 26857/26958 is located in the 5' UTR and provides 
information if the complete Viaat promoter has integrated. Primer pair 2521/24016 is 
located in the IRES-Venus sequence and can be used to distinguish between the two types of 
transgenic animals. Primer pair 26859/26860 is located in the bacterial backbone pBACe3.6, 
which should have been removed by the NruI digestion, and if this was successful, the PCR 
result would be negative.  
 
Figure 28: Illustration of the BAC constructs used for pronuclear injection. (A) Viaat-HA-cEPOR (B) Viaat-HA-
cEPOR-IRES-Venus. Bacterial backbone pBACe3.6, which should have been removed by NruI digestion, 





From 57 Viaat-HA-cEPOR pubs, six animals carried the transgene and showed a PCR product 
of 410 bp with the primer pair 25763/25764 (Figure 29). The mouse identification numbers 
(IDs) were D14-0023, D14-0028, D14-0034, D14-0044, D14-0053 and D14-0055. From 87 
Viaat-HA-cEPOR-IRES-Venus pubs, another six animals were positive for the transgene with 
the following mouse IDs D13-0062, D13-0069, D13-0085, D13-0091, D13-0096 and D13-
0099. All founders (F0 animals positive for the transgene) included the complete 5' Viaat 
promoter, as shown by the PCR product of 751 bp with the primer pair 26857/26958. As 
expected, all Viaat-HA-cEPOR transgenic animals were negative for IRES-Venus, whereas all 
transgenic Viaat-HA-cEPOR-IRES-Venus animals contained the gene for the fluorescent 
marker, as indicated by the PCR product of 615 bp with the primer pair 2521/24016. Some 
founders were not only positive for the construct but also for the bacterial backbone 
pBACe3.6, as demonstrated by the PCR product of 260 bp with the primer pair 26859/26860. 
 
Figure 29: Inverted agarose gel pictures showing the products of the genotyping PCR of the transgenic F0 
generation (founders).  
 
It is well known that the generation of transgenic animals with pronuclear injection has 
some limitations (Ohtsuka et al., 2012). The injected DNA gets integrated at random 
locations into the genome, is integrated with different copy numbers, and may even be 
integrated at multiple sites into the genome. The first hint of different copy numbers 
integrated, was given by the genotyping PCR with the primer pairs 25763/25764 and 
5063/5064 (Figure 29). Compared to the PCR product of IL-2, which can be seen as an 
endogenous housekeeper, the transgenic PCR product varies; e.g. founder D14-0023 showed 
for example a much higher amount of the transgenic product compared to the PCR product 
of IL-2, and D14-0044 had approximately equal amounts of the PCR products. The product 
intensities were further evaluated densitometrically using Fiji and the ratios are shown in 





highest copy number and D13-0062, D13-0091 and D13-0099 only a low copy number 
integrated. All mice with lower or comparable band strength compared to IL-2 were marked 
with one star (*), mice with stronger construct PCR products compared to IL-2 were marked 
with two stars (**). However, copy 
number is not the only factor that 
influences the amount of transgene 
expression. In addition, the integration 
location plays a role and can result in 
varying transgene expression levels.  
Figure 30: Ratio of PCR products (polyA/IL-2) 
of the transgenic F0 generation. 
 
 
These variations highlight, why it is important to analyze each founder separately. All 
founders were bred with C57BL/6N mice to start 12 separate mouse lines. 9 different lines 
could successfully be established: founder D14-0034 was not fertile, D14-0044 had not 
enough transgenic offspring to establish a mouse line and D13-0069 had no transgenic 
offspring at all. From all other founders, it was possible to create a small mouse cohort, 
which was genotyped and further analyzed. In one mouse line (D14-0023) the F1 generation 
had a very unusual, conspicuously high number of transgenic offspring (72 % out of 64 
animals). Additionally, their polyA/IL-2 ratio was split into two distinct groups. An exemplary 
genotyping gel is shown in Figure 31A. Some offspring showed a very strong upper band like 
the founder animal D14-0023, but there were also some animals having equal intensities 
compared to IL-2. The relative numbers of these offspring groups are shown in Figure 31B.  
 
Figure 31: Genotyping of the F1-Generation of the mouse line D14-0023. (A) Inverted agarose gel picture 
visualizing the genotyping PCR products with the primers 25763/25764 and 5063/5064. Animals with the 
strong transgenic product are labeled with two stars; animals with equal amounts of both products are labeled 
with one star. (B) Table of the number and percentages of the F1-generation groups. (C) Agarose gel of 







These results led to the conclusion that the construct had been integrated into two different 
chromosomes (for illustration see Figure 32). Next it was important to know if both 
chromosomes had integrated the complete 5' promoter region. Animals with high and low 
copy numbers were genotyped with the 5' Viaat primer pair 26857/26958 and both groups 
had the complete 5' Viaat promoter integrated (Figure 31C). Additionally, all animals were 
genotyped for the backbone with the primer pair 26859/26860. Interestingly, the animals 
with the low copy number showed no band for the backbone (Figure 31C). Therefore, it is 
possible to distinguish between animals with the low copy number (*) and with the high 
copy number (**) via PCR. Unfortunately, it is not possible to detect if high copy number 
animals are also carrier of the low copy number chromosome.  
 
Figure 32: Illustration of the construct integration in 2 chromosomes (line D14-0023) and the F1 segregation 
when F0 is bred to wt C57BL/6N. 
 
3.2.2 Analysis of the construct expression by immunohistochemistry 
As for the alpha-CaMKII-HA-cEPOR mice, the detection of the construct expression by 
immunohistochemistry was rather difficult. Three different staining methods were tested in 
the mouse line D13-0085 with primary antibodies against HA and GFP (IRES-Venus). The 
methods used were (I) a common indirect fluorescent staining method, (II) a biotin-
streptavidin enhanced indirect fluorescent staining method, and (III) an ABC/TSA enhanced 
indirect fluorescent staining method. With the primary anti-GFP antibody, weakly positive 






Figure 33: Fluorescent immunohistochemistry of the mouse line D14-0085 with the primary antibodies anti-
GFP (A-C) and anti-HA (D-F) using different staining methods. The staining method giving the best result is 





The staining increased if method III was used with the anti-GFP antibody, but there were 
also false positive cells in the wt animal (Figure 33C, C'). In contrast, the primary antibody 
against HA showed no false positive cells in all three staining methods (Figure 33D, E, F) and 
with the ABC/TSA enhanced staining method many positive cells could be visualized (Figure 
33F'). Therefore this method was used for the following experiments.  
To compare the expression in the different mouse lines, coronal sections of 4-6 week old 
animals were double stained against the HA-tag and the GABAergic marker parvalbumin. 
Parvalbumin is expressed in a subpopulation of interneurons and was used to confirm the 
expression in the correct cell type. For illustration, the CA3 area of the hippocampus was 
chosen. In the first run, the wt, tg* and tg** animals of line D14-0023 were stained against 
the HA-tag (red) and parvalbumin (green) (Figure 34). The tg* animal showed less HA-tag 
positive cells compared to tg** animal. In both mice, colocalization of HA and parvalbumin 
could be shown (arrows). In the wt, no HA-tag positive cells were detectable, confirming 
again the specificity of the antibody. 
 
 
Figure 34: Fluorescent immunohistochemistry of the mouse line D14-0023 showing interneurons in the CA3 
region of the hippocampus positive for the construct (HA-tag in red) and parvalbumin (green). Colocalized 






Even though we were especially interested in mouse line D14-0023, all other mouse lines 
were also analyzed by immunohistochemistry for construct expression (Figure 35, Figure 36). 
In the second run, the Viaat-HA-cEPOR lines D14-0028, D14-0053, and D14-0055 were 
analyzed (Figure 35). All three mouse lines showed a robust transgene expression and 
positive cells were colocalized with parvalbumin positive cells. Although the strongest 
transgene expression had been observed in mouse line D14-0055, this mouse line was 
excluded from further analysis because of poor breeding performance.  
 
Figure 35: Fluorescent immunohistochemistry of the mouse lines D14-0028, D14-0053, and D15-0055 
showing interneurons in the CA3 region of the hippocampus positive for the construct (HA-tag in red) and 
parvalbumin (green). Colocalized cells appear in yellow (arrows). Scale bar: 100 µm. 
 
 
In the third run, the Viaat-HA-cEPOR-IRES-Venus mouse lines were analyzed. The transgene 
expression varied considerably in these mouse lines. For mouse line D13-0062, it was not 
possible to detect any construct expression (two transgenic animals analyzed). Mouse lines 
D13-0085 and D13-0096 had a robust transgene expression, D13-0091 showed a weaker 
expression, and D13-0099 had only a few weakly stained positive cells and almost no 
colocalization with parvalbumin positive cells. All together, the staining against the HA-tag 





less positive cells and a lower expression compared to tg** lines. However, it is not clear if 
the tg* lines have truly less cells expressing the construct or if the expression is below the 
detection limit of the used staining procedure.  
 
Figure 36: Fluorescent immunohistochemistry of the mouse lines D13-0062, D13-0085, D13-0091, D13-0096, 
and D13-0099 showing interneurons in the CA3 region of the hippocampus that are positive for the construct 







3.2.3 Summary of all mouse lines 
The characterization of all mouse lines is summarized in Table 3. This table includes the 
breeding performance, the relative amount of integrated construct copy number, the 
integration of the backbone, the construct expression and the information on whether the 
line was preserved via cryoconservation (sperm freezing). Line D14-0023 was chosen for 
further analysis, because of its special feature of having the construct integrated in two 
different chromosomes with different copy numbers. This allows the analysis of expression 
level dependent effects of cEPOR. Line D14-0053 would be the second line of choice. This 
mouse line had a good breeding performance, no backbone integrated, and a robust 
construct expression. Mouse line D14-0053 could be analyzed to reproduce the most 
important findings of mouse line D14-0023, however, this is not part of this thesis.  
 
















3.3 Analysis of mouse line D14-0023 (Viaat-HA-cEPOR) 
3.3.1 EPOR expression in the brain of D14-0023 
For further analysis of the F2 generation, mouse line D14-0023 was used. First the mRNA 
expression of total EPOR was analyzed by qPCR. The used primer pair cannot distinguish 
between the endogenous EPOR and the transgenic cEPOR. Therefore, the amount of EPOR 
as well as cEPOR was detected. Three different brain areas, the hippocampus (HP), the 
cortex (CX), and the cerebellum (CB) were investigated. As expected, the EPOR (cEPOR) 
expression was significantly increased in the transgenic mice (Figure 37A). In the CX of tg* 
female mice, the expression did not reach significance with n=3. In all investigated brain 
areas, the analysis of the female animals confirmed that the tg** mice have a significantly 
higher construct expression than the tg* mice. In the male animals, the pattern looked 
similar (Figure 37B).  
 
Figure 37: Expression of cEPOR in the hippocampus (HP), cortex (CX) and cerebellum (CB). (A) Bar graph of 
EPOR mRNA expression in females (n=3). (B) Bar graph of EPOR mRNA expression in males (n=2). (C) Bar graph 
of cEPOR protein amount in females (n=3). (D) Bar graph of cEPOR protein amount in males (n=2). (E) Example 
Western blot of cEPOR and GAPDH (female). (F) Example Western blot of cEPOR and GAPDH (male). 
Mean±SEM presented; *P≤0.05, **P≤0.01, ***P≤0.001 (unpaired t-test) tg* and tg** of each brain area 






P≤0.001 (unpaired t-test) tg* of each brain area 





Additionally, the cEPOR expression was analyzed on the protein level by Western blot 
(Figure 37C-F). In contrast to the qPCR, the Western blot was specific for cEPOR by using an 
antibody against the HA-tag. As for the qPCR results, the cEPOR was detectable in the HP, 
CX, and strongest in the CB of the tg** mice. In the tg* mice, it was hardly detectable in the 
HP, not in the CX, and relatively strong in the CB. 
3.3.2 Hematocrit 
To exclude that the expression of cEPOR in GABAergic and glycinergic neurons affects the 
proliferation and differentiation of erythrocyte precursor cells, the hematocrit was 
measured. As demonstrated in Figure 38, the 
hematocrit level of the tg** animals does not differ 
from wt mice. 
 
Figure 38: Level of hematocrit of 6-12 week old female and male 
mice. Number of animals: female wt=10, tg**=10; male wt=2, 
tg**=6. Mean ±SEM shown. 
 
3.3.3 Body weight 
During the behavioral analyses, the body weight was measured regularly (Figure 39). After 
combining two mouse cohorts, tg** females showed a significantly reduced body weight at 
an age of 28 - 31 weeks (Figure 39C). However, neither the tg* female and male nor the tg** 
male mice showed a significant difference at that age (Figure 39C, F).  
3.3.4 Behavior analysis 
Male and female mice of the F2 generation were first analyzed for anxiety-related behavior 
by elevated plus maze (Figure 40A-C). Laboratory mice exhibit an innate fear of open, 
unsheltered, and elevated spaces and thus avoid the open arms of an elevated plus-maze. 
Neither the tg* nor the tg** mice showed differences in the time they spent in the open or 
closed arm as compared to the wt mice. After the elevated-plus maze, the animals were 
subjected to the open field test (Figure 40D-F). In this test, the overall activity of the mice is 
represented by the distance traveled. There were no differences between tg*, tg**, and wt 
mice. Additionally, anxiety-like behavior (center avoidance) was measured by analyzing the 
time spent in the center zone of the open field arena. Again, no differences between 
genotypes could be observed. Furthermore, no differences were observed for the 






Figure 39: Body weight of two cohorts of mice (female and male). (A) First cohort of female mice. (B) Second 
cohort of female mice. (C) Bar graph of both cohorts of female mice at the age of 28-31 weeks. (D) First cohort 
of male mice. (E) Second cohort of male mice. (F) Bar graph of both cohorts of male mice at the age of 28-31 
weeks. Mean ±SEM shown; **P≤0.01 (unpaired t-test) tg** compared to wt.  
 
 
Figure 40: Transgenic female and male mice show normal behavior in basic tasks such as elevated plus maze 
(A-C), open field (D-F), and rotarod (G-I). For all tests, animal numbers were as follows: female wt=12, tg*=15, 





The rotarod was used to measure motor coordination and balancing performance. There 
were no differences between groups. Summarizing the first set of tests, one can conclude 
that the transgenic mice do not show significant differences in tasks measuring basic 
behaviors such as anxiety-like behavior, overall activity, or motor performance.  
Next, the mice were evaluated for sensorimotor gating by prepulse inhibition (PPI). PPI is the 
phenomenon of the reduction of the acoustic startle response to a test stimulus if a less 
intense stimulus precedes the test stimulus. It has been proposed that PPI is mediated by a 
circuit of a fast excitatory and a slower inhibitory pathway that are activated in parallel 
(Larrauri and Schmajuk, 2006). In principle, an activation of the inhibitory neurons would 
result in a stronger pre-pulse inhibition. However, female and male mice showed no 
significant difference in PPI (Figure 41A, B). In addition, the startle response itself can also be 
used as a hearing test. For this purpose, a tone of 10 kHz was applied randomly at different 
intensities. Again, no difference was found between wt and transgenic mice (Figure 41C, D). 
After having tested the hearing capability of the transgenic mice, olfaction and pain 
perception were analyzed. Olfaction was measured as the latency to find buried food. As a 
test for pain perception the hot plate test was performed. Both tests showed no differences 
of the tg mice compared to wt (Figure 41E-H). 
To summarize, all basic behavior tests show results for tg mice that are indistinguishable 
from wt. Therefore, the prerequisite for sophisticated cognitive testing is provided. 
 
Figure 41: Transgenic female and male mice are normal in prepulse inhibition (PPI) (A, B), hearing (C, D), 
olfaction (E, F), and pain perceptions (G, H). For all tests, animal numbers were as the follows: female wt=12, 





Spatial reference and working memory (hole board) 
A comprehensive cognitive test, which was used to analyze learning and memory, is the hole 
board test. The test includes the following phases: habituation, acquisition, long-term 
retention, and reversal learning. During habituation, the mice were trained with sucrose 
solution to investigate each of the 16 holes. In the second phase, the acquisition stage, only 
4 out of the 16 holes were baited with the sucrose solution. The mice were tested with two 
trials per day for 6 days and had to learn and remember the location of the baited holes. In 
the test, two forms of spatial memory can be discriminated: 1. spatial reference memory 
(rule learning; remembering which holes are baited) and 2. spatial working memory (which 
holes have been already visited). The transgenic mice showed no differences in reference 
memory and spatial working memory when analyzed with ANOVA for repeated measures 
over all trials (Figure 42A, B).  
 
Figure 42: Transgenic male mice showed no difference in reference memory but in working memory in the 
hole board test. (A) Line graph of spatial reference memory. (B) Line graph of spatial working memory. Two 
trials were performed per day with an inter-trial interval of 2.5h. Data were analyzed with repeated measures 
ANOVA. Data are presented as mean ±SEM. 
 
The transition from the habituation phase to the acquisition phase involves changes in the 
general procedure as well as the reinforcement contingencies, including a reduction in the 
number of rewards available (16 during habituation and 4 during acquisition), a change in 
the maximal trial duration (15 min vs. 5 min), and the number of trials per day (1 vs. 2). 
Therefore, the acquisition phase is composed of a procedural and rule learning stage (day 1 
and 2, trial 1-4), where the animals have to learn that the task requirements have been 
changed, followed by the acquisition of the spatial relations between extra-maze cues and 





In these first two days of acquisition, the transgenic animals performed significantly worse in 
working memory (tg** vs. wt p=0.035, tg* vs. wt p=0.004; repeated measures ANOVA). 
Here, no difference between the low tg* and high tg** expressers was detected. In contrast, 
in the long-term retention and reversal phase of the test no differences were found in tg 
mice compared to wt. These findings indicate that cEPOR expression in inhibitory 
interneurons (Viaat) influences discrete aspects of higher cognitive function, best described 
as procedural or rule learning capacity. 
3.3.5 Electrophysiology – kainate induced gamma oscillation  
GABAergic and glycinergic interneurons are the main source of inhibition in the central 
nervous system and play a major role in neuronal network stabilization and oscillation. 
Gamma oscillations, with frequencies of 30-80 Hz, are known to be associated with higher 
brain functions (Fries et al., 2007; Jensen et al., 2007) and were therefore a very interesting 
readout of the study. Gamma oscillations were induced by the addition of kainate in acute 
hippocampal slices of 6 week old male tg** and wt mice. 
 
Figure 43: Kainate induced gamma oscillations in transgenic tg** male mice do not differ from wt. (A) 
Illustration of kainate induced oscillations, computed power spectrum as well as the analyzed parameters. (B-E) 
Bar graphs presenting the frequency and the power of the maximum peak and the mean power and area in the 




 20min of measured field potentials. 





Baseline field-potentials were recorded in the CA3 region for 20 min before the addition of 
kainate and 2 times 20 min (1st and 2nd) with addition of 100 nM kainate in ACSF buffer. The 
power spectrum was computed and analyzed (for illustration see Figure 43A). The analyzed 
parameters were the power and frequency of the maximum peak and the mean power and 
area of the 25-45 Hz frequency interval. The tg** male mice showed no significant 
differences compared to wt animals (Figure 43B-E).  
3.3.6 Electrophysiology – short and long term potentiation (STP and LTP) 
Long term potentiation (LTP) is accepted as an electrophysiological correlate for synaptic 
plasticity and memory consolidation (Bliss and Collingridge, 1993; Cooke and Bliss, 2006) and 
was measured in the Schaffer collateral CA1 pathway of the hippocampus. As for the gamma 
oscillations, we used tg** male mice for STP and LTP determinations. The basal synaptic 
function in the transgenic tg** male mice was judged on the basis of the input-output curves 
and was comparable to wt mice (Figure 44A). The LTP was induced by applying 3 tetanic 
stimuli of 100 Hz for 1s every 5 min and calculated by averaging the normalized fEPSP 
amplitude collected over 60 min after the last tetanic stimulus. STP was defined as the 
response in the first 10 min after the last titanic stimuli and was found to be significantly 
increased in the tg** mice compared to wt (tg** vs. wt, 1-10 min, genotype effect p=0.023, 
1-way ANOVA for repeated measures; Figure 44B). The LTP showed comparable significances 
measured 10-60 min or 50-60 min after the last titanic stimulus. (tg** vs. wt, 10-60 min, 
genotype effect p=0.030; tg** vs. wt, 50-60 min, genotype effect p=0.025; 1-way ANOVA for 
repeated measures; Figure 44B). 
 
Figure 44: Electrophysiological analysis of the tg** male mice showed (A) no differences in the input-output 
curves; animals numbers: wt=7, tg**=7; slices numbers wt=16, tg**=18. (B) However, a significant increase 
was observed in LTP compared to wt mice; animals numbers: wt=7, tg**=6; slices numbers wt=11, tg**=10. 






In this work, a transgenic mouse line expressing a constitutively active EPOR (cEPOR) in 
inhibitory interneurons was generated to provide further insight into the role of the 
EPO/EPOR system and the relative contribution of distinct neuronal subpopulations to EPO-
mediated effects on cognitive functions. 
The project was based on results showing that systemically administered EPO is able to 
increase cognitive performance in mouse (Adamcio et al., 2008; El-Kordi et al., 2009) and 
man (Bartels et al., 2008; Ehrenreich et al., 2007b; Miskowiak et al., 2008). However, none of 
these studies focused on the underlying mechanisms or the cell type specific contribution to 
this phenomenon. Since EPO and EPOR are expressed in various cell types of the brain, 
including different subpopulations of neurons, oligodendrocytes and microglia, it is of 
interest to dissect the particular impact of these different cell types on the networks of 
cellular interactions and how they contribute to cognitive performance. For this, the 
EPO/EPOR system would have to be activated or inactivated in specific cell types. The first 
study, where the EPO/EPOR system was activated in a subpopulation of neurons, was 
published in 2011 (Sargin et al., 2011). There, a transgenic mouse line was generated that 
expresses the cEPOR in excitatory neurons under the alpha-CaMKII promoter. This 
transgenic mouse line showed increased hippocampal-dependent learning, social memory, 
attention and LTP compared to wt. However, the mouse showed also hyperactivity and 
impulsivity, which was not observed under systemically administered EPO (Table 1). This was 
discussed to result from a continuous stimulation of the EPO system exclusively in cortical 
projection neurons, leading to a relative deficit of inhibitory input and a disturbance of the 
homeostatic balance of excitation and inhibition in the brain (Sargin et al., 2011). This thesis 
continued the analysis of the cell type specific effects of the EPO/EPOR system in the brain. 
This time, the cEPOR was specifically expressed in GABAergic and glycinergic interneurons to 
examine the effect of EPO/EPOR activation in an inhibitory subpopulation of neurons in the 
brain.  
4.1 Expression of cEPOR in inhibitory interneurons  
Inhibitory interneurons are a very heterogeneous neuronal population and are classified by 





2004). One feature, which almost all inhibitory neurons in the brain have in common, is the 
expression of GABA, the main inhibitory transmitter of the brain. A shared property is 
therefore the commonly expressed vesicular GABA transporter (VGAT). Since the transporter 
shuttles not only GABA but also the inhibitory transmitter glycine, the revised name is 
vesicular inhibitory amino acid transporter (Viaat). We used the Viaat BAC RP23-392P11 as 
promoter to express cEPOR in the majority of inhibitory interneurons in the central nervous 
system. The BAC RP23-392P11 includes not only the Viaat gene, which is around 5 kb in size 
and consists of two exons and one intron, but also the upstream and downstream promoter 
region of 125 kb and 68 kb. Using BACs in the generation of transgenic animals has the 
advantage of a relatively independent transgene expression in terms of the genetic 
integration site. In the case of the Viaat-HA-cEPOR±IRES-Venus mice, the usage of the BAC 
RP23-392P11 was successful. In eight out of nine analyzed transgenic mouse lines, the 
expression could be visualized and colocalized with parvalbumin. The differences found in 
the amount of transgene expression were mainly dependent on the inserted copy number 
and less on the site of integration. 
One question, that could not be answered, is why the expression of the construct was 
relatively low. This was also observed for the cEPOR expression in alpha-CaMKII-HA-cEPOR 
mice. At that time, it was speculated that the HA-tag might be causing the problem. The HA-
tag is a very short peptide of nine amino acids that is widely assumed to have a low impact 
on the natural structure and bioactivity of the proteins. However, the short sequence causes 
difficulties in the development of specific antibodies and reduces the number of antibodies, 
able to bind to the epitope. Problems of specificity also became apparent in this study. From 
four antibodies tested (results not shown), only two were specific in immunohistochemistry: 
the monoclonal rabbit anti-HA from Cell Signaling and the monoclonal mouse anti-HA from 
Covance. The polyclonal rabbit anti-HA from Abcam and the monoclonal rat anti-HA from 
Roche showed false positive cells. In order to achieve a better detection rate in the newly 
generated transgenic mouse, an internal fluorescent marker (IRES-Venus) was additionally 
inserted. However, this did not result in an appreciable improvement of detection 
sensitivity. Therefore, the low abundance seems to be inherent to cEPOR rather than being 
caused by the method of detection. Since a regulation on the level of transcription can be 
excluded, cEPOR might be restricted on the translational level or by a fast internalization and 





4.2 Analysis of the Viaat-HA-cEPOR line D14-0023 
It is well known that the generation of transgenic animals with pronuclear injection has 
some limitations (Ohtsuka et al., 2012) and that the injected DNA gets integrated randomly 
and with different copy numbers. Therefore, each founder is unique and can express the 
construct in different intensities and in variable percentages of cells. Thus, it is common to 
analyze the founder lines separately and crossbreeding is rather unusual. One challenge is 
the selection of one or two lines for further analysis, since it is in general not possible to 
characterize all lines in detail. In this study, nine mouse lines were established and analyzed 
for transgene expression. One line that was chosen for further analysis showed the rare 
event of an insertion of the construct in two different chromosomes, which resulted in two 
distinct groups of very high and very low expressers in the offspring. This line (D14-0023) 
was behaviorally examined in anxiety-like behavior, overall activity, motor performance, PPI, 
hearing, olfaction, pain, spatial reference memory, and working memory. In summary, the 
transgenic mice showed no significant differences in their basic behavior. This situation is 
actually an ideal prerequisite for testing higher cognitive functions, since most readouts used 
for judging cognition are dependent on e.g. normal motor performance and activity. The 
mice were then analyzed with the reference and working memory version of the hole board 
test. Here, the transgenic mice showed reduced performance in rule learning during the 
acquisition phase. This is the first indication that the activated EPO/EPOR system in 
inhibitory neurons influences higher brain functions. To get further mechanistic inside, the 
Viaat-HA-cEPOR mice were electrophysiologically examined. The kainate induced gamma 
oscillation showed a strong tendency to be reduced in their power, and more experiments 
are currently running to clarify whether this effect can be consolidated. Additionally, 
hippocampal slices of the animals were tested for STP and LTP, which had earlier been 
shown to be increased after systemically administered EPO as well as in alpha-CaMKII-HA-
cEPOR mice. Interestingly, the Viaat-HA-cEPOR mice showed comparable increased STP and 
LTP. 
4.2.1 Gamma oscillation and memory formation 
It is one of the most challenging tasks in the field of neuroscience to identify the cellular and 
molecular processes underlying cognitive performance and memory formation (Lynch, 





have gained considerable attention in the field. Gamma oscillations are hypothesized to 
modulate cognitive processes and are altered in psychiatric diseases including schizophrenia, 
autism, and anxiety disorders (Sohal, 2012). The rhythmic network inhibition by gamma 
oscillations, also postulated as gamma cycle (Fries et al., 2007), is thought to synchronize the 
network activity and thereby to organize the brain processes necessary for cognitive 
function (Ward, 2003). As mentioned above, the transgenic mice showed an overall 
tendency of a decreased power of gamma oscillations. This may be consistent with the slight 
reduction found in initial rule learning in a working memory task. More tests of higher 
cognitive functions are currently under way. 
4.2.2 LTP and memory formation 
In contrast to the gamma oscillations, the transgenic mice showed increased STP and LTP 
compared to wt mice. On first thought, it is difficult to accommodate a reduced cognitive 
performance in spatial working memory with increased LTP, since LTP is the most popular 
cellular readout for learning and memory (Cooke and Bliss, 2006; Lynch, 2004). However, 
there are increasing numbers of publications discussing and questioning the causal role of 
LTP for memory formation (Gerlai, 2002). Some reviews conclude that LTP is necessary but 
might be not sufficient for learning and memory (Martin et al., 2000) and others pursue the 
question if there is a role of LTP in memory formation at all (Goda and Stevens, 1996; 
Stevens, 1998). The latter proposition was mainly formed after experiments showing that 
blocked or decreased LTP in the dentate gyrus, the Schaffer collateral pathway or the mossy 
fiber pathway had no effects on spatial memory (Huang et al., 1995; Nosten-Bertrand et al., 
1996; Qi et al., 1996; Saucier and Cain, 1995). Later on, publications indicated that increased 
LTP did not equate with increased learning and memory. Moreover, it was even shown, that 
increased LTP can be found in mice with decreased spatial memory (Migaud et al., 1998; 
Pineda et al., 2004; Uetani et al., 2000). Summarizing these studies, only severe LTP defects 
seem to impair spatial memory and decreased spatial memory is also present in animal 
models with increased LTP. One explanation discussed (Migaud et al., 1998) is a model of 
synaptic plasticity that includes bidirectional modifications of synaptic strength (potentiation 
and depression). If too many synapses become strongly potentiated and not enough 
depressed, this might result in a degradation of information storage and recall capacity, 





Finally, it is not only the question of how increased LTP can be linked to decreased memory 
formation, but also the question of how cEPOR expression in interneurons is able to increase 
LTP, which is an extracellular measurement of the activity of excitatory neurons. 
4.2.3 Comparison with EPO treated and with alpha-CaMKII-HA-cEPOR mice  
Getting back to the analysis of the specific impact of the EPO/EPOR system in neuronal 
subtypes on cognition, the so far achieved results of the Viaat-HA-cEPOR mice were 
compared with the results of systemically administered EPO (Adamcio et al., 2008) and the 
alpha-CaMKII-HA-cEPOR mice (Sargin et al., 2011) (Table 4). Here, the systemically 
administered EPO was seen as a collective model representing the sum of EPO action in all 
types of cells expressing the EPOR (inside as well as outside the brain). Of interest would be 
how the different cell types in the brain add to this picture. The first readout that was 
analyzed in all three models was spontaneous activity, which was unchanged after 
systematically administered EPO, but increased in alpha-CaMKII-HA-cEPOR mice. This was 
discussed to be caused by an excitatory/inhibitory imbalance and a relative deficit of 
inhibition (Sargin et al., 2011). It was hypothesized that an expression of cEPOR in inhibitory 
interneurons might strengthen the inhibitory output leading to reverse effects and reduced 
activity. However, the first results showed no decrease of activity in the Viaat-HA-cEPOR 
mice. 
  
Table 4: Comparison of the EPO effects, if systemically administered, constitutively active in excitatory 
pyramidal cells (alpha-CaMKII-HA-cEPOR-mice) or constitutively active in inhibitory interneurons (Viaat-Ha-
cEPOR mice). = no change,  increased,  decreased. 
 
Furthermore, the kainate induced gamma oscillation result suggests that the interneurons 
are rather decreased in their power than increased. This was consistent with the first 
cognitive readout, which showed a mild cognitive impairment in the Viaat-HA-cEPOR mice. 
These results contrast the effect of EPO treatment as well as cEPOR expression in excitatory 
neurons, where a significant improvement of cognitive performance was observed. Further 





Comparing the electrophysiological readouts, it was interesting to find all three models 
sharing the phenotype of increased STP and LTP, demonstrating the role of the EPO/EPOR 
system on potentiation of the synaptic strength. However, EPO did not change the basal 
excitability of the neurons, as seen in the input-output curves, in the EPO treated and the 
Viaat-HA-cEPOR transgenic mice, whereas the alpha-CaMKII-HA-cEPOR mice showed a 
decreased basal excitability.  
4.2.4 Body weight and metabolism 
During this study, an inconspicuous but very interesting discovery was made. The female 
transgenic mice were significantly reduced in their body weight at an age of 28-31 weeks, 
suggesting a role of the EPO/EPOR system on energy homeostasis. In fact, the first indication 
of EPO influencing metabolism was found in end-stage renal disease patients, who were 
treated with EPO (Khedr et al., 2009; Rasic-Milutinovic et al., 2008; Tuzcu et al., 2004) and 
showed improved insulin sensitivity. Recent studies suggest EPO as a beneficial treatment 
for type 2 diabetes, and showed improved glucose tolerance and inhibition of 
gluconeogenesis (Meng et al., 2013). The effect of EPO on metabolism was also determined 
in the EPOR-/- knockout animals, which were rescued for the blood system (EPOR-/- TgEPORE). 
Initially, these mice developed normally to start with and were fertile, but developed obesity 
and insulin resistance later in their life (Teng et al., 2011). Interestingly, the effect was more 
obvious in female mice as compared to male mice. Therefore, in our case, it is remarkable 
that the opposite effect is present in a transgenic mouse line with cEPOR expression in 
interneurons. This allows at least two speculative hypotheses. First, cEPOR expression in the 
inhibitory interneurons of the hypothalamus influences energy homeostasis (decreased food 
uptake and/or increased energy expenditure). Second, EPO could increase glucose uptake in 
general. This would be supported by the expression pattern of EPOR. EPOR is expressed at 
high levels in precursor cells or during hypoxic stress conditions, and in both cases the cells 





In this study, a transgenic mouse line expressing cEPOR in inhibitory interneurons was 
generated and analyzed. First results indicate that the mouse is normal in its basic behavior, 
but has a mild cognitive impairment, which manifests in deficits in spatial working memory. 
Additionally, the mouse was electrophysiologically analyzed and showed an increase in STP 
and LTP. However, the analysis of the newly generated transgenic mouse line is not finalized 
yet, and more experiments are planned to describe the phenotype in more detail.  
The planned experiments can be divided into three categories:  
1.) Behavior analysis  
2.) Electrophysiological analysis  
3.) Cellular and biochemical analysis 
For the behavior analysis, we plan several further experiments. One is the analysis of the tg* 
and tg** mice in the Morris water maze, which is another tests of spatial learning and 
memory. Furthermore, it is planned to use the touch screen task to test higher brain 
functions, fear conditioning as an additional readout for hippocampal learning and memory, 
and marble burring, which can be used to analyze repetitive behavior or impulsivity.  
For the electrophysiological analysis we are currently collecting data of the paired pulse 
facilitation as readout of short term plasticity, and we are also increasing the number of 
acute slices measuring kainate induced gamma oscillation. Analyses of long and short term 
depression (STD, LTD), as well as of low frequency oscillations, are currently considered for 
further experiments. Those results might help to understand how cEPOR expression in 
inhibitory interneurons is able to increase the network activity in form of LTP, to modulate 
synaptic strength, and to decrease in the end the cognitive performance. 
The third category includes the cellular and biochemical analysis of the transgenic mouse 
line. One aspect, which has not been considered so far, is the effect of EPO on the 
differentiation of neural precursor cells. This phenomenon is explained in detail in the 
manuscript of the appendix. Therefore, it cannot be ruled out that cEPOR influences the 
differentiation of interneurons during embryonic development, since the Viaat promoter 
activity starts as early as E10 (Oh et al., 2005). This might result in a change of the total 
number of interneurons and we have already started counting Viaat-positive interneurons in 





VGAT-Venus transgenic mouse line (Wang et al., 2009), to fluorescently label all Viaat-
positive cells. In the same experiment, the percentage of Viaat-positive cells expressing the 
HA-cEPOR construct will be evaluated.  
One interesting aspect of EPO action is the hypothesized influence on energy homeostasis 
and metabolism. We will analyze the protein turnover as metabolic readout, which can be 
measured by multi-isotope imaging mass spectrometry (MIMS) (Zhang et al., 2012). For this 
method, the mice are fed with food containing L[15N]leucine, an amino acid labeled with a 
stable isotope. Newly synthesized protein will accumulate the isotope and will be become 
detectable with MIMS. If cEPOR is indeed increasing the protein turnover, the interneurons 
should then show a more pronounced 15N signal. 
 
In summary, a new transgenic mouse line has been created in the current study. This line 
expresses the constitutively active EPOR in inhibitory interneurons. The already conducted 
initial analyses show very promising results but further experiments are necessary to 
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7 Appendix  
In agreement with the first reviewer, Prof. Dr. Dr. Hannelore Ehrenreich, the second 
reviewer, Prof. Dr. Klaus-Armin Nave, and the speaker of the doctoral program (Center for 
Systems Neuroscience), Prof. Dr. Stefan Treue, the appendix with the manuscript draft of 
thesis project 1, is not published in the official version of the thesis. Its publication as an 
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